Clinical characteristics.

For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut⁰ enzymatic subtype or mut^– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included:

• Infantile/non-B₁₂-responsive form (mut⁰ enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B₁₂-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy.
• Partially deficient or B₁₂-responsive phenotypes (mut^– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation
• Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures.

In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.

Diagnosis/testing.

The diagnosis of isolated MMA is established in a proband by identification of biallelic pathogenic variants in MCEE, MMAA, MMAB, MMADHC, or MMUT or (in some instances) by significantly reduced activity of one of the following enzymes: methylmalonyl-CoA mutase, methylmalonyl-CoA mutase enzyme cofactor 5'-deoxyadenosylcobalamin, or methylmalonyl-CoA epimerase. Because of its relatively high sensitivity, easier accessibility, and noninvasive nature, molecular genetic testing can obviate the need for enzymatic testing in most instances.

Management.

Treatment of manifestations / Prevention of primary manifestations: When isolated MMA is suspected during the diagnostic evaluation due to elevated propionylcarnitine (C3) on a newborn blood spot, metabolic treatment should be initiated immediately, while the suspected diagnosis is being confirmed. Development and evaluation of treatment plans, training and education of affected individuals and their families, and avoidance of side effects of dietary treatment (i.e., malnutrition, growth failure) require a multidisciplinary approach by experienced subspecialists from a specialized metabolic center. The main principles of treatment are to provide supplemental vitamin B₁₂ to those who are known to be vitamin B₁₂ responsive; restrict natural protein, particularly of propiogenic amino acid precursors, while maintaining a high-calorie diet; address feeding difficulties, recurrent vomiting, and growth failure; provide supplemental carnitine to those with carnitine deficiency; reduce propionate production from gut flora; and provide emergency treatment during episodes of acute decompensation with the goal of averting catabolism and minimizing central nervous system injury. In those with significant metabolic instability and/or renal failure, liver and/or renal transplantation may be considered.

Prevention of secondary complications: MedicAlert^® bracelets and up-to-date, easily accessed, detailed emergency treatment and presurgical protocols to facilitate care.

Surveillance: Regular evaluations by a metabolic specialist and metabolic dietician; screening laboratory testing, including plasma amino acids, plasma and urine MMA levels, serum acylcarnitine profile and free and total carnitine levels, blood chemistries, and complete blood count at least every six months to one year, or more frequently in infants or in those who are unstable or require frequent changes in dietary management; measurement of renal function at least annually or as clinically indicated; assessment for liver disease at least annually or as clinically indicated; assessment of developmental progress and for signs of movement disorder at each visit; ophthalmology evaluation to monitor for optic atrophy at least annually or as clinically indicated; audiology evaluation at least annually in childhood and adolescence or as clinically indicated.

Agents/circumstances to avoid: Fasting, stress, increased dietary protein, supplementation with the individual propiogenic amino acids valine and isoleucine, nephrotoxic medications or agents, and agents that prolong QTc in the EKG.

Evaluation of relatives at risk: For at-risk newborn sibs when prenatal testing was not performed: in parallel with newborn screening, measure serum methylmalonic acid, urine organic acids, plasma acylcarnitine profile, plasma amino acids, and serum B₁₂; test for the familial isolated methylmalonic acidemia-causing pathogenic variants if biochemistry is abnormal.

Pregnancy management for an affected mother: Monitor for complications including acute decompensation or hyperammonemia, deterioration of renal function, and obstetric complications including preeclampsia and preterm delivery.

Pregnancy management for an unaffected mother with an affected fetus: Oral and intramuscular vitamin B₁₂ has been administered to women pregnant with a fetus with vitamin B₁₂-responsive MMA, resulting in decreased maternal MMA urine output; however, further study of this treatment is needed.

Genetic counseling.

All forms of isolated MMA are inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an isolated MMA-causing pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of inheriting neither of the familial pathogenic variants. Once the isolated MMA-causing pathogenic variants have been identified in an affected family member, molecular genetic carrier testing and prenatal/preimplantation genetic testing are possible.

Suggestive Findings

Scenario 1: Abnormal Newborn Screening (NBS) Result

Newborn screening test. NBS for isolated methylmalonic acidemia is primarily based on quantification of the analyte propionylcarnitine (C3) on dried blood spots.

Elevated C3 values above the cutoff reported by the screening laboratory are considered positive and require follow-up biochemical testing (see also the ACMG ACT Sheet).

• In the US, individual state NBS programs determine cutoffs based on analytic and other considerations, under the guidance of the CDC Newborn Screening Quality Assurance Program (NSQAP) and Association of Public Health Laboratories (APHL) [McHugh et al 2011, Held et al 2022].
• Since propionylcarnitine is one of the analytes most frequently responsible for false positive results, ratios including C3/C2, C3/C0, C3/C16, C3/glycine, or C3/methionine are recommended in combination with high blood concentration of C3 as decision criteria for "positive" testing in newborn screening acylcarnitine analysis by MS/MS for methylmalonic acidemia and propionic acidemia [Gavrilov et al 2020].
• Additional biomarkers such as C16:1OH (3-hydroxypalmitoleolyl-carnitine) or, more accurately, C17 (heptadecanoylcarnitine) have been suggested to improve the sensitivity of the first-tier newborn screening test [McHugh et al 2011, Malvagia et al 2015].
• Amino acid analysis of the dried blood spot will show normal methionine and elevated C3/methionine ratio.
• Precision newborn screening and avoidance of false positive results can be further improved with the utilization of the Collaborative Laboratory Integrated Reports software [Gavrilov et al 2020].

The following medical interventions need to begin immediately on receipt of an abnormal NBS result while additional testing is performed to determine whether this is a true positive NBS result and to establish the diagnosis of isolated MMA definitively (see Management):

• Prompt evaluation for prevention or treatment of possible hyperammonemia and metabolic ketoacidosis
• Daily intramuscular vitamin B₁₂ administration (Hydroxocobalamin is preferred over cyanocobalamin, especially in individuals with cobalamin C deficiency.)
• Initiation of a low-protein diet
• Carnitine supplementation

Testing to consider after a positive NBS. A positive C3 screening result is followed by testing for methylmalonic acid, 2-methylcitrate, and total homocysteine in the dried blood spot to differentiate isolated MMA from propionic acidemia and defects resulting in combined methylmalonic acidemia and homocystinuria [Turgeon et al 2010, Weiss et al 2020, Pajares et al 2021].

Follow-up biochemical testing after an abnormal NBS typically demonstrates:

• Elevated plasma methylmalonic acid (MMA) level
• Elevated levels of urine MMA and the presence of 3-hydroxypropionate, 2-methylcitrate, and tiglylglycine on urine organic acids
• Elevated concentrations of glycine and possibly alanine with normal methionine on plasma amino acids
• Elevated plasma concentration of propionylcarnitine (C3) and variable elevations in C4-dicarboxylic or methylmalonic/succinylcarnitine (C4DC) on plasma acylcarnitine profile
• Elevated plasma ammonia, metabolic ketoacidosis, pancytopenia, lactic acidosis, hypoglycemia (in some cases)
• Normal serum B₁₂ and plasma homocysteine

Note: (1) Although plasma and/or urine methylmalonic acid concentration can be precisely quantitated (see Table 1), this is generally not needed immediately for diagnostic purposes. (2) If MMA is confirmed, further biochemical testing of plasma homocysteine and serum vitamin B₁₂ (in both the newborn and the mother) helps further differentiate the cause of MMA (see Figure 2, left two columns).

Figure 2.

An algorithm of conditions to be considered in the differential diagnosis of elevated serum or urine methylmalonic acid detected either during the follow up of an increased propionylcarnitine (C3) on newborn screening or following a positive urine organic (more...)

If follow-up biochemical testing supports the likelihood of isolated methylmalonic acidemia, additional testing is required to establish the diagnosis (see Establishing the Diagnosis).

Establishing the Diagnosis

The diagnosis of isolated MMA is established in a proband by identification of biallelic pathogenic variants in one of the genes listed in Table 2 on molecular genetic testing or – in some instances – by significantly reduced activity of the enzymes listed below and in Table 1. Because of its relatively high sensitivity, easier accessibility, and noninvasive nature, molecular genetic testing can obviate the need for enzymatic testing, and is thus increasingly the preferred confirmatory test for isolated MMA.

Isolated MMA is caused by any ONE of the following:

• Complete (mut⁰ enzymatic subtype) or partial (mut^–) deficiency of the enzyme methylmalonyl-CoA mutase, encoded by MMUT
• Diminished synthesis of the methylmalonyl-CoA mutase enzyme cofactor 5'-deoxyadenosylcobalamin, associated with cblA, cblB, or cblD-MMA complementation groups caused by biallelic pathogenic variants in MMAA, MMAB, or MMADHC, respectively
• Deficient activity of methylmalonyl-coenzyme A epimerase encoded by MCEE

Molecular genetic testing (see Table 2) can be used to establish the diagnosis of isolated MMA by identifying biallelic pathogenic variants in one of the genes listed in Table 2 and confirming carrier status in the parents.

Clinical Description

The phenotypes of isolated methylmalonic acidemia (MMA) described below that are associated with the enzymatic subtypes mut⁰, mut^–, cblA, cblB, and cblD-MMA share clinical presentations and a natural history characterized by periods of relative health and intermittent metabolic decompensation, usually associated with intercurrent infections and stress [Zwickler et al 2012]. Each such decompensation can be life threatening. Table 3 reviews the phenotypes, causative genes, enzymatic subtypes, and clinical correlations that will be discussed further in this section.

Genotype-Phenotype Correlations

Precise genotype-phenotype correlations are difficult to determine since most affected individuals are compound heterozygotes and many pathogenic variants are not recurrent in the population.

MMAB

• c.556C>T (p.Arg186Trp). This is the most common pathogenic variant, present in 29%-33% of alleles from European and North American cohorts [Lerner-Ellis et al 2006, Forny et al 2022].
  Individuals homozygous for this pathogenic variant typically present in the neonatal period and are not responsive to hydroxocobalamin treatment.
• c.700C>T (p.Gln234Ter). Individuals with at least one c.700C>T (p.Gln234Ter) pathogenic variant generally have more variable, often later age of presentation/diagnosis (range: 2 days – 6.5 years) and some affected individuals demonstrate a biochemical response to hydroxocobalamin therapy [Forny et al 2022]. This variant is located in the last exon and may avoid nonsense-mediated decay, resulting in a partially functional protein.

MMADHC. Truncating pathogenic variants in the N-terminal region (exons 3, 4) cause isolated methylmalonic aciduria due to a defect in adenosylcobalamin synthesis; pathogenic variants elsewhere in this gene cause the other two biochemical phenotypes (see Genetically Related Disorders).

MMUT. The phenomenon of interallelic complementation makes prediction of genotype/phenotype/enzyme activity difficult because some individuals who have two pathogenic variants can have a mut^– enzymatic subtype in the compound state but a mut⁰ enzymatic subtype in the homozygous state [Acquaviva et al 2005].

• Persons with two truncating pathogenic variants usually have the mut⁰ enzymatic subtype.
• Most of the pathogenic variants identified in the N-terminal domain have been associated with mut⁰ enzymatic subtype of methylmalonic acidemia [Acquaviva et al 2005, Forny et al 2016]
• The mut^– enzymatic subtype is known to be associated mostly, but not exclusively, with pathogenic variants in the adenosylcobalamin-binding C-terminal domain of the MMUT protein.
• The mut^– enzymatic subtype pathogenic variant usually plays a dominant role when in compound heterozygous state with a mut⁰ enzymatic subtype pathogenic variant, given a OH-Cbl response in the in vitro assay [Lempp et al 2007, Forny et al 2016].
• A linker domain spanning residues 482-585 separates the N-terminal, or substrate (methylmalonyl-CoA) binding domain from the C-terminal cobalamin-binding domain. This linker region is less conserved and has a lower frequency of pathogenic variants [Forny et al 2016].

Prevalence

Several studies have estimated the birth prevalence of isolated methylmalonic acidemia. Urine screening for isolated methylmalonic acidemia in Quebec identified "symptomatic methylmalonic aciduria" in approximately 1:80,000 newborns screened [Sniderman et al 1999].

The aggregate incidence from different newborn screening (NBS) programs in the US is reported as 1:159,614 [Therrell et al 2014, Chapman et al 2018]. A meta-analysis [Almási et al 2019] confirmed that the detection rate of MMA and isolated MMA in North America, Europe and Asia-Pacific regions was <1:100,000, while rates in the Middle East, North Africa, and Japan were higher [Shigematsu et al 2002].

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with isolated MMA, the evaluations summarized Table 6 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Treatment of Manifestations

Guidelines developed by professionals across 12 European countries and the US based on rigorous literature evaluation and expert group meetings outline the current management recommendations and areas for further research. See Baumgartner et al [2014] (full text) and Forny et al [2021] (full text).

Acute manifestations (e.g., lethargy, encephalopathy, seizures, or progressive coma), often occurring in the setting of intercurrent illness and/or inadequate caloric intake, should be managed symptomatically and with generous caloric support in a hospital setting, with aggressive treatment and supportive care. Immediate consultation with a metabolic/biochemical geneticist is essential. Individuals with MMA can deteriorate rapidly and consultations with neurology, nephrology, and ICU teams are often required during crises (see Table 10).

Transition from pediatric to adult-centered multidisciplinary care settings. As MMA is a lifelong disorder with varying implications according to age, smooth transition of care from the pediatric setting is essential for long-term management and should be organized as a well-planned, continuous, multidisciplinary process integrating resources of all relevant subspecialties. Standardized procedures for transitional care do not exist for isolated MMA due to the absence of multidisciplinary outpatient departments.

• Transitional care concepts have been developed in which adult internal medicine specialists initially see individuals with isolated methylmalonic acidemia together with pediatric or adult metabolic experts, dietitians, psychologists, and social workers.
• As the long-term course of pediatric metabolic diseases in this age group is not yet fully characterized and there is limited availability of clinics for adults with IEMs, continuous supervision by a center with expertise in metabolic diseases with sufficient resources is essential.

Prevention of Primary Manifestations

See also Table 7, which outlines dietary therapies that can help to prevent a metabolic crisis.

Large case series of affected individuals undergoing elective liver or combined liver/kidney transplantation (as opposed to isolated kidney transplantation) have detailed the indications, peri-operative complications, surgical and anesthesia approaches, anti-rejection regimens, and long-term outcomes in people with MMA undergoing these procedures. Inclusion of enzymatic and genotype information in case series of transplanted individuals allows for better comparisons of the outcomes and genotype-phenotype associations that could inform decisions about the indication and timing of transplantation in individual cases.

Liver transplantation is increasingly offered to younger affected individuals with significant metabolic instability, often in infancy, as a measure to prevent neurologic damage from recurrent metabolic crises associated with hyperammonemia. Referral to centers with experience in managing people with organic acidemias and continued monitoring and dietary therapy are essential for all MMA transplant recipients.

Antioxidants. One individual with isolated MMA who was documented to be glutathione deficient after a severe metabolic crisis responded to ascorbate therapy [Treacy et al 1996]. Several studies document increased oxidative stress, glutathione depletion, and specific respiratory chain complex deficiencies in persons with the mut⁰ enzymatic subtype of MMA [Atkuri et al 2009, Chandler et al 2009, de Keyzer et al 2009, Manoli et al 2013], suggesting a potential benefit of treatment with antioxidants or other mitochondria-targeted therapies in these individuals.

A regimen of coenzyme Q₁₀ and vitamin E has been shown to prevent progression of acute optic nerve involvement in a patient with MMA [Pinar-Sueiro et al 2010]. Thiamine can help with severe lactic acidosis by overcoming pyruvate dehydrogenase inhibition during the treatment of acute metabolic crises (see Table 10). Whether chronic administration of CoQ10, vitamin E, or N-acetylcysteine could prevent long-term complications requires further study [Haijes et al 2019b].

Base replacement. Individuals with MMUT methylmalonic academia (subtype mut⁰ or mut^-) have renal tubular dysfunction and low-grade chronic acidosis that can accelerate the progression of their chronic kidney disease. Sodium bicarbonate or citrate (Bicitra^®) replacement aiming for a serum bicarbonate concentration of 22-24 µmol/L, is recommended per standard guidelines for management of chronic kidney disease in children [KDOQI Work Group 2009, Brown et al 2020]. Bicitra has the additional benefit of offering citrate for TCA cycle anaplerosis and was studied in propionic acidemia [Longo et al 2017]. Polycitra contains potassium, which should be monitored closely due to the risk of developing hyperkalemia in individuals with kidney disease.

Prevention of Secondary Complications

One of the most important components of management (as it relates to prevention of secondary complications) is education of parents and caregivers such that diligent observation and management can be administered expediently in the setting of intercurrent illness or other catabolic stressors (see also Tables 9 and 10). Adherence to a low-protein diet and frequent monitoring by the primary metabolic clinic (see Table 13), as well as continued care by other specialists (nephrologist, neurologist, gastroenterologist, cardiologist, and others), is necessary throughout life.

Surveillance

During the first year of life, infants may need to be evaluated as frequently as every week and continued at intervals determined by the frequency of metabolic crises/admissions, growth patterns, and dietary needs. Attention to transition periods (e.g., after the first two years, in adolescence) with other stressors in the family are necessary for modification of dietary prescription.

In addition to regular evaluations by a metabolic specialist and metabolic dietician, the following are recommended. See Table 13.

Agents/Circumstances to Avoid

The following should be avoided:

• Fasting. During acute illness, intake of adequate calories is necessary to arrest/prevent decompensation.
• Stress
• Increased dietary protein
• Supplementation with the individual propiogenic amino acids valine and isoleucine, as they directly increase the toxic metabolite load in patients with disordered propionate oxidation [Nyhan et al 1973, Hauser et al 2011, Manoli et al 2016b]
• Nephrotoxic medications or agents (e.g. ibuprofen)
• Agents that prolong QTc in the EKG

Evaluation of Relatives at Risk

Evaluation of all at-risk sibs of any age is warranted to allow for early diagnosis and treatment of isolated methylmalonic acidemia.

For at-risk newborn sibs when prenatal testing was not performed: in parallel with newborn screening, measure serum methylmalonic acid, urine organic acids, plasma acylcarnitine profile, plasma amino acids, and serum B₁₂; and test for the familial isolated methylmalonic acidemia-causing pathogenic variants if biochemistry is abnormal.

Prenatal diagnosis of at-risk sibs may allow for prompt treatment of affected newborns at the time of delivery or prenatal administration of vitamin B₁₂ in responsive subtypes, especially cblA.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

Affected mother

• In pregnancies of affected women with MMA, complications observed included acute decompensation or hyperammonemia, deterioration of renal function, and obstetric complications including preeclampsia, preterm delivery, and cæsarean section [Raval et al 2015].
• Despite high maternal MMA levels, fetal growth and development have been reported to be normal, suggesting negligible teratogenic effects to the fetus from exposure to high methylmalonic acid levels in utero, though long-term follow up with age-appropriate neurocognitive testing is limited [Wasserstein et al 1999, Deodato et al 2002].
• Pregnancies in transplant recipients are rare and further studies on the health of the offspring are needed [Marcellino et al 2021].

Unaffected mother with an affected fetus. Oral and intramuscular vitamin B₁₂ has been administered to women pregnant with a fetus with vitamin B₁₂-responsive MMA, resulting in decreased maternal MMA urine output [Ampola et al 1975, van der Meer et al 1990]. These observations notwithstanding, maternal vitamin B₁₂ supplementation for isolated MMA needs further study.

See MotherToBaby for further information on medication use during pregnancy.

Therapies Under Investigation

13-C-propionate breath test. A stable isotope 13-C-propionate breath test has been developed as a surrogate biomarker of disease severity and was shown to correlate with in vitro 14-C-propionate incorporation, isolated MMA subtype, and several disease-related manifestations (rate of progression of chronic renal disease, growth parameters, and cognitive outcomes). Moreover, it showed a response to B₁₂ supplementation or solid organ transplantation [Manoli et al 2021]. It can be used in specialized centers to help prognosticate disease severity and select affected individuals with very low oxidation rates for referral to transplantation or clinical trials testing novel genomic therapies.

Increased understanding of the underlying pathophysiology and the generation of disease-specific animal or cellular models has allowed the development of several novel therapies for isolated MMA [Chandler & Venditti 2019, Luciani et al 2020, Dimitrov et al 2021, Head et al 2022]. The effect of each of these therapeutic approaches on the long-term clinical outcomes of MMA remains to be elucidated.

• Liver-targeted genomic therapies including systemic canonic recombinant adeno-associated virus (rAAV) gene therapy [Chandler & Venditti 2008, Carrillo-Carrasco et al 2010, Chandler & Venditti 2010, Chandler & Venditti 2012, Sénac et al 2012, Chandler et al 2021], systemic mRNA replacement [An et al 2017], and genome editing into the albumin locus [Chandler et al 2021] have shown significant promise in animal models and are reaching Phase I/II clinical trials as promising alternatives to liver transplantation.
• Studies using primary hepatocytes from individuals with methylmalonic and propionic acidemia have found that administration of the small molecule 2,2-dimethylbutanoic acid (HST5040) leads to a dose dependent reduction in levels of methylmalonyl-CoA and other serum metabolites. This small molecule is being tested in clinical trials [Armstrong et al 2021].
• Investigational therapies intended to increase CoA levels by allosterically modulating pantothenate kinases, key enzymes in the CoA biosynthesis pathway, have been shown to increase free CoA and alleviate mitochondrial dysfunction in mouse models of propionic academia (PA) [Subramanian et al 2021] and are being tested in clinical trials for MMA and PA.
• Carefully designed clinical studies are required to evaluate the efficacy of antioxidant regimens in people with MMA.

Review the following for more information on current clinical trials on isolated MMA:

clinicaltrials.gov/ct2/show/NCT04581785

clinicaltrials.gov/ct2/show/NCT04732429

clinicaltrials.gov/ct2/show/NCT04899310

clinicaltrials.gov/ct2/show/NCT04836494

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.

Mode of Inheritance

All forms of isolated methylmalonic acidemia (MMA) – including complete or partial deficiency of the enzyme methylmalonyl-CoA mutase; defect in transport or synthesis of the methylmalonyl-CoA mutase cofactor, 5'deoxyadenosyl-cobalamin; and deficiency of the enzyme methylmalonyl-CoA epimerase – are inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

• The parents of an affected child are presumed to be heterozygous for an MMUT, MMAA, MMAB, MCEE, or MMADHC pathogenic variant.
• If a molecular diagnosis has been established in the proband, molecular genetic testing is recommended for the parents of the proband to confirm that both parents are heterozygous for an isolated MMA-causing pathogenic variant and to allow reliable recurrence risk assessment. If a pathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:
  • One of the pathogenic variants identified in the proband occurred as a de novo event in the proband or as a postzygotic de novo event in a mosaic parent [Jónsson et al 2017].
  • Uniparental isodisomy for the parental chromosome with the pathogenic variant resulted in homozygosity for the pathogenic variant in the proband. Uniparental isodisomy has been reported (MMUT [id(6)pat] and MMAA [segmental upd(4)mat] [Abramowicz et al 1994, Chen et al 2020].)
• Heterozygotes (carriers) of a pathogenic variant in an isolated MMA-related gene (i.e., MMUT, MMAA, MMAB, MCEE, or MMADHC) have normal metabolite concentrations.

Sibs of a proband

• If both parents are known to be heterozygous for an isolated MMA-causing pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of inheriting neither of the familial pathogenic variants.
• Heterozygotes (carriers) of a pathogenic variant in an isolated MMA-causing gene (i.e., MMUT, MMAA, MMAB, MCEE, or MMADHC) have normal metabolite concentrations.

Offspring of a proband. Unless an affected individual's reproductive partner also has isolated MMA or is a carrier, offspring will be obligate heterozygotes (carriers) for a pathogenic variant in an isolated MMA-related gene.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of an isolated MMA-causing pathogenic variant.

Carrier Detection

• Carrier testing for at-risk relatives requires prior identification of the isolated MMA-causing pathogenic variants in the family.
• MMUT is included in the recommended gene list for carrier screening (Tier II) and may be included on expanded carrier screening panels [Gregg et al 2021].

Methods other than molecular genetic testing are not reliable for carrier testing.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on testing at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

DNA banking. Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see Huang et al [2022].

Prenatal Testing and Preimplantation Genetic Testing

Molecular genetic testing. Once the isolated MMA-causing pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Biochemical testing. Both amniotic fluid measurements for methylmalonic acid and cellular biochemical assays (¹⁴C propionate incorporation and complementation assays) on cultured fetal cells obtained by amniocentesis or chorionic villus sampling have been used for prenatal testing [Morel et al 2005]. However, due to the limited availability and longer turnaround time for cellular biochemical assays, the preferred method for prenatal diagnosis is molecular genetic testing.

Molecular Pathogenesis

Isolated MMA results from the failure to isomerize (convert) methylmalonyl-CoA into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid (Figure 1). Several different enzyme deficiencies affecting these metabolic steps can cause isolated MMA (Figure 2), including the methylmalonyl-CoA mutase itself and those providing the adenosylcobalamin as a cofactor. MMAA encodes a GTPase critical for the mitochondrial assembly of adenosylcobalamin (AdoCbl) to the methylmalonyl-CoA enzyme [Froese et al 2010]. MMAB encodes an ATP:cob(I)alamin adenosyltransferase (ATR) that transfers 5′-deoxyadenosyl from ATP to Cbl forming AdoCbl and delivers it to the methylmalonyl-CoA enzyme. MMUT encodes methylmalonyl-CoA mutase, a mitochondrial enzyme that catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA, which requires AdoCbl as coenzyme. MMADHC encodes a protein necessary in the early metabolic pathway of AdoCbl formation.

Aberrant post-translational modifications (methylmalonylation) have inhibitory effects on critical enzymes in the urea cycle and glycine cleavage pathways, causing the secondary disease manifestations such as hyperammonemia and hyperglycinemia in MMA [Head et al 2022].

Plasma fibroblast growth factor 21 (FGF21) has been characterized as a marker of hepatic mitochondrial dysfunction in MMA murine models and was shown to correlate with disease severity and long-term complications in different patient cohorts [Manoli et al 2018, Molema et al 2018, Manoli et al 2021].

Mechanism of disease causation. Loss of function

Notable variants by gene. See Table 4 for a list of specific pathogenic MMUT variants, that when in a homozygous state, lead to a specific predicted enzymatic phenotype. Further notable pathogenic variants by gene are listed in Table 15.

Author Notes

Dr Manoli is a pediatrician and clinical and biochemical geneticist. She is a clinician associate investigator and senior staff clinician in the Organic Acid Research Section of the National Human Genome Research Institute, and an attending physician at the National Institutes of Health Clinical Center.

Dr Sloan is a genetic counselor, molecular geneticist, and cytogeneticist. She is a staff scientist in the Organic Acid Research Section of the National Human Genome Research Institute.

Dr Venditti is a pediatrician and clinical and biochemical geneticist. He is a senior investigator and the director of the Organic Acid Research Section at the National Human Genome Research Institute and an attending physician at the National Institutes of Health Clinical Center.

Websites:

www.genome.gov/staff/Charles-P-Venditti-MD-PhD

www.genome.gov/about-nhgri/Division-of-Intramural-Research/Metabolic-Medicine-Branch

Acknowledgments

The authors are supported by the Intramural Research Program of the National Human Genome Research Institute, Bethesda, MD. They have a longitudinal natural history protocol on methylmalonic acidemias and cobalamin disorders at the NIH (Study URL: clinicaltrials.gov/ct2/show/NCT00078078) and a focused interest on translational research in these disorders. Further details and contact information are provided at the group's website: www.genome.gov/Current-NHGRI-Clinical-Studies/Methylmalonic-Acidemia-MMA.

The authors wish to acknowledge the non-profit organizations "Angels for Alyssa," "A Cure for Clark," and the Organic Acidemia Association (OAA), all founded by families and friends of patients with MMA, for their ongoing dedication and support of MMA research.

Revision History

• 8 September 2022 (ma) Comprehensive update posted live
• 1 December 2016 (cpv) Revision: Molecular Genetics: MMAB and MMUT
• 7 January 2016 (me) Comprehensive update posted live
• 28 September 2010 (me) Comprehensive update posted live
• 18 January 2007 (cd) Revision: testing for mutations in MMAA and MMAB clinically available
• 16 August 2005 (me) Review posted live
• 11 May 2004 (cpv) Original submission

Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the GeneReview "Isolated Methylmalonic Acidemia" is in the public domain in the United States of America.

Literature Cited

• Abdrabo LS, Watkins D, Wang SR, Lafond-Lapalme J, Riviere JB, Rosenblatt DS. Genome and RNA sequencing in patients with methylmalonic aciduria of unknown cause. Genet Med. 2020;22:432-6. [PubMed: 31462756]
• Abramowicz MJ, Andrien M, Dupont E, Dorchy H, Parma J, Duprez L, Ledley FD, Courtens W, Vamos E. Isodisomy of chromosome 6 in a newborn with methylmalonic acidemia and agenesis of pancreatic beta cells causing diabetes mellitus. J Clin Invest. 1994;94:418-21. [PMC free article: PMC296325] [PubMed: 7913714]
• Acquaviva C, Benoist JF, Pereira S, Callebaut I, Koskas T, Porquet D, Elion J Molecular basis of methylmalonyl-CoA mutase apoenzyme defect in 40 European patients affected by mut(o) and mut- forms of methylmalonic acidemia: identification of 29 novel mutations in the MUT gene. Hum Mutat 2005;25:167-76 [PubMed: 15643616]
• Adjalla CE, Hosack AR, Matiaszuk NV, Rosenblatt DS. A common mutation among blacks with mut- methylmalonic aciduria. Hum Mutat. 1998;Suppl 1:S248-50. [PubMed: 9452100]
• Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126:e208-14. [PMC free article: PMC3297024] [PubMed: 20566609]
• Aldubayan SH, Rodan LH, Berry GT, Levy HL. Acute illness protocol for organic acidemias: methylmalonic acidemia and propionic acidemia. Pediatr Emerg Care. 2017;33:142-6. [PubMed: 28141776]
• Alfadhel M, Nashabat M, Saleh M, Elamin M, Alfares A, Al Othaim A, Umair M, Ahmed H, Ababneh F, Al Mutairi F, Eyaid W, Alswaid A, Alohali L, Faqeih E, Almannai M, Aljeraisy M, Albdah B, Hussein MA, Rahbeeni Z, Alasmari A. Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial. Orphanet J Rare Dis. 2021;16:422. [PMC free article: PMC8507242] [PubMed: 34635114]
• Alfares A, Nunez LD, Al-Thihli K, Mitchell J, Melançon S, Anastasio N, Ha KC, Majewski J, Rosenblatt DS, Braverman N. Combined malonic and methylmalonic aciduria: exome sequencing reveals mutations in the ACSF3 gene in patients with a non-classic phenotype. J Med Genet. 2011;48:602-5. [PubMed: 21785126]
• Alizadeh Najjarbashi F, Mesdaghi M, Alaei M, Shakiba M, Jami A, Ghadimi F. A study on the humoral and complement immune system of patients with organic acidemia. Iran J Allergy Asthma Immunol. 2015;14:638-41. [PubMed: 26725562]
• Almási T, Guey LT, Lukacs C, Csetneki K, Voko Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency. Orphanet J Rare Dis. 2019;14:84. [PMC free article: PMC6485056] [PubMed: 31023387]
• Al-Owain M, Freehauf C, Bernstein L, Kappy M, Thomas J. Growth hormone deficiency associated with methylmalonic acidemia. J Pediatr Endocrinol Metab. 2004;17:239-43. [PubMed: 15055362]
• Al-Owain M, Khalifa OA, Al Sahlawi Z, Hussein MH, Sulaiman RA, Al-Sayed M, Rahbeeni Z, Al-Hassnan Z, Al-Zaidan H, Nezzar H, Al Homoud I, Eldali A, Altonen B, Handoom BS, Mbekeani JN. Optic neuropathy in classical methylmalonic acidemia. Ophthalmic Genet. 2019;40:313-22. [PubMed: 31269850]
• Altun I, Kiykim A, Zubarioglu T, Burtecene N, Hopurcuoglu D, Topcu B, Cansever MS, Kiykim E, Cezmi Cokugras H, Aktuglu Zeybek AC. Altered immune response in organic acidemia. Pediatr Int. 2022;64:e15082. [PubMed: 34861062]
• Ampola MG, Mahoney MJ, Nakamura E, Tanaka K. Prenatal therapy of a patient with vitamin-B12-responsive methylmalonic acidemia. N Engl J Med. 1975;293:313-7. [PubMed: 239344]
• An, D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, Theisen M, Hong SJ, Zhou J, Rajendran R, Levy B, Howell R, Besin G, Presnyak V, Sabnis S, Murphy-Benenato KE, Kumarasinghe ES, Salerno T, Mihai C, Lukacs CM, Chandler RJ, Guey LT, Venditti CP, and Martini PGV. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep 2017;21:3548-58 [PMC free article: PMC9667413] [PubMed: 29262333]
• Andréasson M, Zetterstrom RH, von Dobeln U, Wedell A, Svenningsson P. MCEE mutations in an adult patient with Parkinson's disease, dementia, stroke and elevated levels of methylmalonic acid. Int J Mol Sci. 2019;20:2631. [PMC free article: PMC6600349] [PubMed: 31146325]
• Armstrong AJ, Collado MS, Henke BR, Olson MW, Hoang SA, Hamilton CA, Pourtaheri TD, Chapman KA, Summar MM, Johns BA, Warmhoff BR, Reardon JE, Figler RA. A novel small molecule approach for the treatment of propionic and methylmalonic acidemias. Mol Genet Metab 2021;133:71-82. [PMC free article: PMC9109253] [PubMed: 33741272]
• Atkuri KR, Cowan TM, Kwan T, Ng A, Herzenberg LA, Herzenberg LA, Enns GM (2009) Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci USA 106:3941-5 [PMC free article: PMC2656184] [PubMed: 19223582]
• Bain MD, Nussey SS, Jones M, Chalmers RA Use of human somatotrophin in the treatment of a patient with methylmalonic aciduria. Eur J Pediatr 1995;154:850-2 [PubMed: 8529687]
• Baker EH, Sloan JL, Hauser NS, Gropman AL, Adams DR, Toro C, Manoli I, Venditti CP. MRI characteristics of globus pallidus infarcts in isolated methylmalonic acidemia. AJNR Am J Neuroradiol. 2015;36:194-201. [PMC free article: PMC7965933] [PubMed: 25190203]
• Bakshi NA, Al-Anzi T, Mohamed SY, Rahbeeni Z, AlSayed M, Al-Owain M, Sulaiman RA. Spectrum of bone marrow pathology and hematological abnormalities in methylmalonic acidemia. Am J Med Genet A. 2018;176:687-91. [PubMed: 29330964]
• Baumgarter ER, Viardot C. Long-term follow-up of 77 patients with isolated methylmalonic acidaemia. J Inherit Metab Dis. 1995;18:138-42 [PubMed: 7564229]
• Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, Huemer M, Hochuli M, Assoun M, Ballhausen D, Burlina A, Fowler B, Grünert SC, Grünewald S, Honzik T, Merinero B, Pérez-Cerdá C, Scholl-Bürgi S, Skovby F, Wijburg F, MacDonald A, Martinelli D, Sass JO, Valayannopoulos V, Chakrapani A. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. [PMC free article: PMC4180313] [PubMed: 25205257]
• Bikker H, Bakker HD, Abeling NG, Poll-The BT, Kleijer WJ, Rosenblatt DS, Waterham HR, Wanders RJ, Duran M A homozygous nonsense mutation in the methylmalonyl-CoA epimerase gene (MCEE) results in mild methylmalonic aciduria. Hum Mutat 2006; 27:640-3 [PubMed: 16752391]
• Brassier A, Boyer O, Valayannopoulos V, Ottolenghi C, Krug P, Cosson MA, Touati G, Arnoux JB, Barbier V, Bahi-Buisson N, Desguerre I, Charbit M, Benoist JF, Dupic L, Aigrain Y, Blanc T, Salomon R, Rabier D, Guest G, de Lonlay P, Niaudet P. Renal transplantation in 4 patients with methylmalonic aciduria: a cell therapy for metabolic disease. Mol Genet Metab. 2013;110:106-10. [PubMed: 23751327]
• Brassier A, Krug P, Lacaille F, Pontoizeau C, Krid S, Sissaoui S, Servais A, Arnoux JB, Legendre C, Charbit M, Scemla A, Francoz C, Benoist JF, Schiff M, Mochel F, Touati G, Broué P, Cano A, Tardieu M, Querciagrossa S, Grévent D, Boyer O, Dupic L, Oualha M, Girard M, Aigrain Y, Debray D, Capito C, Ottolenghi C, Salomon R, Chardot C, de Lonlay P. Long-term outcome of methylmalonic aciduria after kidney, liver, or combined liver-kidney transplantation: the French experience. J Inherit Metab Dis. 2020;43:234-43. [PubMed: 31525265]
• Brown DD, Roem J, Ng DK, Reidy KJ, Kumar J, Abramowitz MK, Mak RH, Furth SL, Schwartz GJ, Warady BA, Kaskel FJ, Melamed ML. Low serum bicarbonate and CKD progression in children. Clin J Am Soc Nephrol. 2020;15:755-65. [PMC free article: PMC7274283] [PubMed: 32467307]
• Campbell CD, Ganesh J, Ficicioglu C. Two newborns with nutritional vitamin B12 deficiency: challenges in newborn screening for vitamin B12 deficiency. Haematologica. 2005;90:ECR45 [PubMed: 16464760]
• Carrillo-Carrasco N, Chandler RJ, Chandrasekaran S, Venditti CP. Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correction. Hum Gene Ther. 2010;21:1147-54. [PMC free article: PMC2936498] [PubMed: 20486773]
• Carrozzo R, Dionisi-Vici C, Steuerwald U, Lucioli S, Deodato F, Di Giandomenico S, Bertini E, Franke B, Kluijtmans LA, Meschini MC, Rizzo C, Piemonte F, Rodenburg R, Santer R, Santorelli FM, van Rooij A, Vermunt-de Koning D, Morava E, Wevers RA (2007) SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain 130:862-74 [PubMed: 17301081]
• Celiker MY, Chawla A. Congenital B12 deficiency following maternal gastric bypass. J Perinatol. 2009;29:640-2. [PubMed: 19710657]
• Chace DH, DiPerna JC, Kalas TA, Johnson RW, Naylor EW (2001) Rapid diagnosis of methylmalonic and propionic acidemias: quantitative tandem mass spectrometric analysis of propionylcarnitine in filter-paper blood specimens obtained from newborns. Clin Chem 47:2040-4 [PubMed: 11673377]
• Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV (2002) Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J Pediatr 140:261-3 [PubMed: 11865284]
• Chambliss KL, Gray RG, Rylance G, Pollitt RJ, Gibson KM. Molecular characterization of methylmalonate semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2000;23:497-504. [PubMed: 10947204]
• Chan R, Mascarenhas L, Boles RG, Kerkar N, Genyk Y, Venkatramani R. Hepatoblastoma in a patient with methylmalonic aciduria. Am J Med Genet A. 2015;167A:635-8. [PubMed: 25691417]
• Chandler RJ, Venditti CP (2008) Adenovirus-mediated gene delivery rescues a neonatal lethal murine model of mut(0) methylmalonic acidemia. Hum Gene Ther 19:53-60 [PMC free article: PMC2683146] [PubMed: 18052792]
• Chandler RJ, Venditti CP. Gene therapy for methylmalonic acidemia: past, present, and future. Hum Gene Ther. 2019;30:1236-44. [PMC free article: PMC6763959] [PubMed: 31303064]
• Chandler RJ, Venditti CP (2010) Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy. Mol Ther. 18:11-6. [PMC free article: PMC2839224] [PubMed: 19861951]
• Chandler RJ, Venditti CP. Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA). Mol Genet Metab. 2012;107:617-9. [PMC free article: PMC3522145] [PubMed: 23046887]
• Chandler RJ, Venturoni LE, Liao J, Hubbard BT, Schneller JL, Hoffmann V, Gordo S, Zang S, Ko CW, Chau N, Chiang K, Kay MA, Barzel A, Venditti CP. Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia. Hepatology. 2021;73:2223-37. [PMC free article: PMC8252383] [PubMed: 32976669]
• Chandler RJ, Zerfas PM, Shanske S, Sloan J, Hoffmann V, DiMauro S, Venditti CP (2009) Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J 23:1252-61 [PMC free article: PMC2660647] [PubMed: 19088183]
• Chang PF, Huang SF, Hwu WL, Hou JW, Ni YH, Chang MH (2000) Metabolic disorders mimicking Reye's syndrome. J Formos Med Assoc 99:295-9 [PubMed: 10870312]
• Chao PW, Chang WK, Lai IW, et al. Acute life-threatening arrhythmias caused by severe hyperkalemia after induction of anesthesia in an infant with methylmalonic acidemia. J Chin Med Assoc. 2012; 75:243–245. [PubMed: 22632992]
• Chapel-Crespo C, Gavrilov D, Sowa M, Myers J, Day-Salvatore DL, Lynn H, Regier D, Starin D, Steenari M, Schoonderwoerd K, Abdenur JE. Clinical, biochemical and molecular characteristics of malonyl-CoA decarboxylase deficiency and long-term follow-up of nine patients. Mol Genet Metab. 2019;128:113-21. [PubMed: 31395333]
• Chapman KA, Gramer G, Viall S, Summar ML. Incidence of maple syrup urine disease, propionic acidemia, and methylmalonic aciduria from newborn screening data. Mol Genet Metab Rep. 2018;15:106-9. [PMC free article: PMC6047110] [PubMed: 30023298]
• Chen M, Hao H, Xiong H, Cai Y, Ma F, Shi C, Xiao X, Li S. Segmental uniparental disomy of chromosome 4 in a patient with methylmalonic acidemia. Mol Genet Genomic Med. 2020;8:e1063. [PMC free article: PMC6978399] [PubMed: 31793236]
• Chu J, Pupavac M, Watkins D, Tian X, Feng Y, Chen S, Fenter R, Zhang VW, Wang J, Wong LJ, Rosenblatt DS. Next generation sequencing of patients with mut methylmalonic aciduria: Validation of somatic cell studies and identification of 16 novel mutations. Mol Genet Metab. 2016;118:264-71. [PubMed: 27233228]
• Chu TH, Chien YH, Lin HY, Liao HC, Ho HJ, Lai CJ, Chiang CC, Lin NC, Yang CF, Hwu WL, Lee NC, Lin SP, Liu CS, Hu RH, Ho MC, Niu DM. Methylmalonic acidemia/propionic acidemia - the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet J Rare Dis. 2019;14:73. [PMC free article: PMC6444613] [PubMed: 30940196]
• Ciani F, Donati MA, Tulli G, Poggi GM, Pasquini E, Rosenblatt DS, Zammarchi E (2000) Lethal late onset cblB methylmalonic aciduria. Crit Care Med 28:2119-21 [PubMed: 10890676]
• Clothier JC, Chakrapani A, Preece MA, McKiernan P, Gupta R, Macdonald A, Hulton SA. Renal transplantation in a boy with methylmalonic acidaemia. J Inherit Metab Dis. 2011;34:695-700. [PubMed: 21416195]
• Coelho D, Suormala T, Stucki M, Lerner-Ellis JP, Rosenblatt DS, Newbold RF, Baumgartner MR, Fowler B (2008) Gene identification for the cblD defect of vitamin B12 metabolism. N Engl J Med. 358:1454-64. [PubMed: 18385497]
• Coman D, Huang J, McTaggart S, Sakamoto O, Ohura T, McGill J, Burke J. Renal transplantation in a 14-year-old girl with vitamin B12-responsive cblA-type methylmalonic acidaemia. Pediatr Nephrol. 2006;21:270-3. [PubMed: 16247646]
• Cosson MA, Benoist JF, Touati G, Dechaux M, Royer N, Grandin L, Jais JP, Boddaert N, Barbier V, Desguerre I, Campeau PM, Rabier D, Valayannopoulos V, Niaudet P, de Lonlay P. Long-term outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab. 2009;97:172-8. [PubMed: 19375370]
• Cosson MA, Touati G, Lacaille F, Valayannnopoulos V, Guyot C, Guest G, Verkarre V, Chrétien D, Rabier D, Munnich A, Benoist JF, de Keyzer Y, Niaudet P, de Lonlay P. Liver hepatoblastoma and multiple OXPHOS deficiency in the follow-up of a patient with methylmalonic aciduria. Mol Genet Metab. 2008;95:107-9. [PubMed: 18676166]
• Coulombe JT, Shih VE, Levy HL. Massachusetts Metabolic Disorders Screening Program. II. Methylmalonic aciduria. Pediatrics. 1981;67:26-31. [PubMed: 7243433]
• Critelli K, McKiernan P, Vockley J, Mazariegos G, Squires RH, Soltys K, Squires JE. Liver transplantation for propionic acidemia and methylmalonic acidemia: perioperative management and clinical outcomes. Liver Transpl. 2018;24:1260-70. [PubMed: 30080956]
• Dao M, Arnoux JB, Bienaimé F, Brassier A, Brazier F, Benoist JF, Pontoizeau C, Ottolenghi C, Krug P, Boyer O, de Lonlay P, Servais A. Long-term renal outcome in methylmalonic acidemia in adolescents and adults. Orphanet J Rare Dis. 2021;16:220. [PMC free article: PMC8120835] [PubMed: 33985557]
• de Baulny HO, Benoist JF, Rigal O, Touati G, Rabier D, Saudubray JM (2005) Methylmalonic and propionic acidaemias: management and outcome. J Inherit Metab Dis. 28:415-23. [PubMed: 15868474]
• de Keyzer Y, Valayannopoulos V, Benoist JF, Batteux F, Lacaille F, Hubert L, Chrétien D, Chadefeaux-Vekemans B, Niaudet P, Touati G, Munnich A, de Lonlay P (2009) Multiple OXPHOS deficiency in the liver, kidney, heart and skeletal muscle of patients with methylmalonic aciduria and propionic aciduria. Pediatr Res 66:91-5 [PubMed: 19342984]
• Deodato F, Rizzo C, Boenzi S, Baiocco F, Sabetta G, Dionisi-Vici C. Successful pregnancy in a woman with mut- methylmalonic acidaemia. J Inherit Metab Dis. 2002;25:133-4. [PubMed: 12118529]
• De Raeve L, De Meirleir L, Ramet J, Vandenplas Y, Gerlo E (1994) Acrodermatitis enteropathica-like cutaneous lesions in organic aciduria. J Pediatr 124:416-20. [PubMed: 8120711]
• Dimitrov B, Molema F, Williams M, Schmiesing J, Mühlhausen C, Baumgartner MR, Schumann A, Kölker S. Organic acidurias: Major gaps, new challenges, and a yet unfulfilled promise. J Inherit Metab Dis. 2021;44:9-21. [PubMed: 32412122]
• Diodato D, Olivieri G, Pro S, Maiorani D, Martinelli D, Deodato F, Taurisano R, Di Capua M, Dionisi-Vici C. Axonal peripheral neuropathy in propionic acidemia: a severe side effect of long-term metronidazole therapy. Neurology. 2018;91:565-7. [PubMed: 30120134]
• Dionisi-Vici C, Deodato F, Röschinger W, Rhead W, Wilcken B (2006) 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis 29:383-9 [PubMed: 16763906]
• Dobrowolski SF, Alodaib A, Karunanidhi A, Basu S, Holecko M, Lichter-Konecki U, Pappan KL, Vockley J. Clinical, biochemical, mitochondrial, and metabolomic aspects of methylmalonate semialdehyde dehydrogenase deficiency: Report of a fifth case. Mol Genet Metab. 2020;129:272-7. [PubMed: 32151545]
• Dobson CM, Gradinger A, Longo N, Wu X, Leclerc D, Lerner-Ellis J, Lemieux M, Belair C, Watkins D, Rosenblatt DS, Gravel RA (2006) Homozygous nonsense mutation in the MCEE gene and siRNA suppression of methylmalonyl-CoA epimerase expression: a novel cause of mild methylmalonic aciduria. Mol Genet Metab 88:327-33 [PubMed: 16697227]
• Dudley J, Allen J, Tizard J, McGraw M (1998) Benign methylmalonic acidemia in a sibship with distal renal tubular acidosis. Pediatr Nephrol 12:564-6 [PubMed: 9761355]
• Dündar H, Özgül RK, Güzel-Ozantürk A, Dursun A, Sivri S, Aliefendioğlu D, Coşkun T, Tokatli A. Microarray based mutational analysis of patients with methylmalonic acidemia: identification of 10 novel mutations. Mol Genet Metab. 2012;106:419-23. [PubMed: 22727635]
• Elpeleg O, Miller C, Hershkovitz E, Bitner-Glindzicz M, Bondi-Rubinstein G, Rahman S, Pagnamenta A, Eshhar S, Saada A (2005) Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet 76:1081-6 [PMC free article: PMC1196446] [PubMed: 15877282]
• Evans M, Truby H, Boneh A. The Relationship between Dietary Intake, Growth, and Body Composition in Inborn Errors of Intermediary Protein Metabolism. J Pediatr. 2017 Sep;188:163-172. [PubMed: 28629683]
• Fattahi Z, Sheikh TI, Musante L, Rasheed M, Taskiran II, Harripaul R, Hu H, Kazeminasab S, Alam MR, Hosseini M, Larti F, Ghaderi Z, Celik A, Ayub M, Ansar M, Haddadi M, Wienker TF, Ropers HH, Kahrizi K, Vincent JB, Najmabadi H. Biallelic missense variants in ZBTB11 can cause intellectual disability in humans. Hum Mol Genet. 2018;27:3177-88. [PubMed: 29893856]
• FitzPatrick DR, Hill A, Tolmie JL, Thorburn DR, Christodoulou J. The molecular basis of malonyl-CoA decarboxylase deficiency. Am J Hum Genet. 1999;65:318-26. [PMC free article: PMC1377930] [PubMed: 10417274]
• Forny P, Davison J, Skeath R, Gruenewald S, Stojanovic J, Hadzic N, Barone G, Vara R, Munir S. 057 GOSH-wide review of pancreatitis as a complication in methylmalonic aciduria. Arch Dis Child. 2018;103:A24.
• Forny P, Froese DS, Suormala T, Yue WW, Baumgartner MR. Functional characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase (MUT) deficiency. Hum Mutat. 2014;35:1449-58. [PMC free article: PMC4441004] [PubMed: 25125334]
• Forny P, Hochuli M, Rahman Y, Deheragoda M, Weber A, Baruteau J, Grunewald S. Liver neoplasms in methylmalonic acidemia. An emerging complication. J Inherit Metab Dis. 2019;42:793-802. [PubMed: 31260114]
• Forny P, Horster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, Dixon M, Gruenrt SC, Grunewald S, Haliloglou G, Hochuli M, Hnozik T, Karall D, Martinelli D, Molema F, Sass JO, Scholl-Burgi E, Tal G, Williams M, Huemer M, Baumgartner MR. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44:566-92. [PMC free article: PMC8252715] [PubMed: 33595124]
• Forny P, Plessi T, Frei C, Burer C, Froese SD, Baumgartner MR. Spectrum and characterization of bi-allelic variants in MMAB causing cblB-type methylmalonic aciduria. Hum Genet. 2022;141:1253-67. [PMC free article: PMC9262797] [PubMed: 34796408]
• Forny P, Schnellmann AS, Buerer C, Lutz S, Fowler B, Froese DS, Baumgartner MR. Molecular Genetic Characterization of 151 Mut-Type Methylmalonic Aciduria Patients and Identification of 41 Novel Mutations in MUT. Hum Mutat. 2016;37:745-54. [PubMed: 27167370]
• Fowler B, Leonard JV, Baumgartner MR (2008) Causes and diagnostic approach to methylmalonic acidurias. J Inherit Metab Dis 31:350-60 [PubMed: 18563633]
• Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016;28:682-93. [PMC free article: PMC5393914] [PubMed: 27653704]
• Froese DS, Forouhar F, Tran TH, Vollmar M, Kim YS, Lew S, Neely H, Seetharaman J, Shen Y, Xiao R, Acton TB, Everett JK, Cannone G, Puranik S, Savitsky P, Krojer T, Pilka ES, Kiyani W, Lee WH, Marsden BD, von Delft F, Allerston CK, Spagnolo L, Gileadi O, Montelione GT, Oppermann U, Yue WW, Tong L. Crystal structures of malonyl-coenzyme A decarboxylase provide insights into its catalytic mechanism and disease-causing mutations. Structure. 2013;21:1182-92. [PMC free article: PMC3701320] [PubMed: 23791943]
• Froese DS, Kochan G, Muniz JR, Wu X, Gileadi C, Ugochukwu E, Krysztofinska E, Gravel RA, Oppermann U, Yue WW. Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation. J Biol Chem. 2010 Dec 3;285(49):38204-13 [PMC free article: PMC2992254] [PubMed: 20876572]
• Froese DS, Kopec J, Fitzpatrick F, Schuller M, McCorvie TJ, Chalk R, Plessi T, Fettelschoss V, Fowler B, Baumgartner MR, Yue WW. Structural insights into the MMACHC-MMADHC protein complex involved in vitamin B12 trafficking. J Biol Chem. 2015;290:29167-77. [PMC free article: PMC4705923] [PubMed: 26483544]
• Gancheva S, Caspari D, Bierwagen A, Jelenik T, Caprio S, Santoro N, Rothe M, Markgraf DF, Herebian D, Hwang JH, Öner-Sieben S, Mennenga J, Pacini G, Thimm E, Schlune A, Meissner T, Vom Dahl S, Klee D, Mayatepek E, Roden M, Ensenauer R. Cardiometabolic risk factor clustering in patients with deficient branched-chain amino acid catabolism: A case-control study. J Inherit Metab Dis. 2020;43:981-93. [PubMed: 32118306]
• Gavrilov DK, Piazza AL, Pino G, Turgeon C, Matern D, Oglesbee D, Raymond K, Tortorelli S, Rinaldo P. The combined impact of CLIR post-analytical tools and second tier testing on the performance of newborn screening for disorders of propionate, methionine and cobalamin metabolism. Int J Neonatal Screen. 2020;6:33. [PMC free article: PMC7423003] [PubMed: 33073028]
• Giorgio AJ, Trowbridge M, Boone AW, Patten RS (1976) Methylmalonic aciduria without vitamin B12 deficiency in an adult sibship. N Engl J Med 295:310-3 [PubMed: 6909]
• González I, Lecube A, Rubio MÁ, García-Luna PP. Pregnancy after bariatric surgery: improving outcomes for mother and child. Int J Womens Health. 2016;8:721-9. [PMC free article: PMC5167470] [PubMed: 28008286]
• Gradinger AB, Bélair C, Worgan LC, Li CD, Lavallée J, Roquis D, Watkins D, Rosenblatt DS. Atypical methylmalonic aciduria: frequency of mutations in the methylmalonyl CoA epimerase gene (MCEE). Hum Mutat. 2007;28:1045. [PubMed: 17823972]
• Gramer G, Fang-Hoffmann J, Feyh P, Klinke G, Monostori P, Mütze U, Posset R, Weiss KH, Hoffmann GF, Okun JG. Newborn screening for vitamin B12 deficiency in Germany—strategies, results, and public health implications. J Pediatr. 2020;216:165-72.e4. [PubMed: 31604629]
• Grange DK, Finlay JL. Nutritional vitamin B12 deficiency in a breastfed infant following maternal gastric bypass. Pediatr Hematol Oncol. 1994;11:311-8. [PubMed: 8060815]
• Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, Chen E, Sparks TN, Reddi HV, Rajkovic A, Dungan JS; ACMG Professional Practice and Guidelines Committee. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:1793-806. [PMC free article: PMC8488021] [PubMed: 34285390]
• Guerra-Moreno J, Barrios N, Santiago-Borrero PJ. Severe neutropenia in an infant with methylmalonic acidemia. Bol Asoc Med P R. 2003;95:17-20. [PubMed: 12898746]
• Haijes HA, Jans JJM, Tas SY, Verhoeven-Duif NM, van Hasselt PM. Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications. J Inherit Metab Dis. 2019a;42:730-44. [PubMed: 31119747]
• Haijes HA, van Hasselt PM, Jans JJM, Verhoeven-Duif NM. Pathophysiology of propionic and methylmalonic acidemias. Part 2: Treatment strategies. J Inherit Metab Dis. 2019b;42:745-61. [PubMed: 31119742]
• Hannah-Shmouni F, Cruz V, Schulze A, Mercimek-Andrews S. Transcobalamin receptor defect: Identification of two new cases through positive newborn screening for propionic/methylmalonic aciduria and long-term outcome. Am J Med Genet A. 2018;176:1411-5. [PubMed: 29663633]
• Harrington EA, Sloan JL, Manoli I, Chandler RJ, Schneider M, McGuire PJ, Calcedo R, Wilson JM, Venditti CP. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia. Hum Gene Ther. 2016;27:345-53. [PMC free article: PMC4841085] [PubMed: 26790480]
• Harting I, Seitz A, Geb S, Zwickler T, Porto L, Lindner M, Kölker S, Hörster F (2008) Looking beyond the basal ganglia: the spectrum of MRI changes in methylmalonic acidaemia. J Inherit Metab Dis. 31:368-78. [PubMed: 18470632]
• Hauser NS, Manoli I, Graf JC, Sloan J, Venditti CP. Variable dietary management of methylmalonic acidemia: metabolic and energetic correlations. Am J Clin Nutr. 2011;93:47-56. [PMC free article: PMC3001598] [PubMed: 21048060]
• Head PE, Myung S, Chen Y, Schneller JL, Wang C, Duncan N, Hoffman P, Chang D, Gebremariam A, Gucek M, Manoli I, Venditti CP. Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin. Sci Transl Med. 2022;14:eabn4772. [PMC free article: PMC10468269] [PubMed: 35613279]
• Heidenreich R, Natowicz M, Hainline BE, Berman P, Kelley RI, Hillman RE, Berry GT (1988) Acute extrapyramidal syndrome in methylmalonic acidemia: "metabolic stroke" involving the globus pallidus. J Pediatr 113:1022-7 [PubMed: 3193307]
• Held PK, Singh E, Scott Schwoerer J. Screening for Methylmalonic and Propionic Acidemia: Clinical Outcomes and Follow-Up Recommendations. Int J Neonatal Screen. 2022;8:13. [PMC free article: PMC8883915] [PubMed: 35225935]
• Heringer J, Valayannopoulos V, Lund AM, Wijburg FA, Freisinger P, Barić I, Baumgartner MR, Burgard P, Burlina AB, Chapman KA, I Saladelafont EC, Karall D, Mühlhausen C, Riches V, Schiff M, Sykut-Cegielska J, Walter JH, Zeman J, Chabrol B, Kölker S, et al. Impact of age at onset and newborn screening on outcome in organic acidurias. J Inherit Metab Dis. 2016;39:341-53. [PubMed: 26689403]
• Heuberger K, Bailey HJ, Burda P, Chaikuad A, Krysztofinska E, Suormala T, Bürer C, Lutz S, Fowler B, Froese DS, Yue WW, Baumgartner MR. Genetic, structural, and functional analysis of pathogenic variations causing methylmalonyl-CoA epimerase deficiency. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1265-72. [PMC free article: PMC6525113] [PubMed: 30682498]
• Hinton CF, Ojodu JA, Fernhoff PM, Rasmussen SA, Scanlon KS, Hannon WH. Maternal and neonatal vitamin B12 deficiency detected through expanded newborn screening--United States, 2003-2007. J Pediatr. 2010;157:162-3. [PubMed: 20400092]
• Hörster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B, Hoffmann GF, Garbade SF, Kölker S, Baumgartner ER (2007) Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut-, cblA, cblB). Pediatr Res. 62:225-30. [PubMed: 17597648]
• Hörster F, Garbade SF, Zwickler T, Aydin HI, Bodamer OA, Burlina AB, Das AM, De Klerk JBC, Dionisi-Vici C, Geb S, Gökcay G, Guffon N, Maier EM, Morava E, Walter JH, Schwahn B, Wijburg FA, Lindner M, Grünewald S, Baumgartner MR, Kölker S. Prediction of outcome in isolated methylmalonic acidurias: combined use of clinical and biochemical parameters. J Inherit Metab Dis. 2009;32:630. [PubMed: 19642010]
• Hörster F, Tuncel AT, Gleich F, Plessl T, Froese SD, Garbade SF, Kölker S, Baumgartner MR, et al. Delineating the clinical spectrum of isolated methylmalonic acidurias: cblA and mut. J Inherit Metab Dis. 2021;44:193-214. [PubMed: 32754920]
• Hsui JY, Chien YH, Chu SY, Lu FL, Chen HL, Ho MJ, Lee PH, Hwu WL. Living-related liver transplantation for methylmalonic acidemia: report of one case. Acta Paediatr Taiwan. 2003;44:171-3. [PubMed: 14521026]
• Huang SJ, Amendola LM, Sternen DL. Variation among DNA banking consent forms: points for clinicians to bank on. J Community Genet. 2022;13:389-97. [PMC free article: PMC9314484] [PubMed: 35834113]
• Hwang WJ, Lim HH, Kim YM, Chang MY, Kil HR, Kim JY, Song WJ, Levy HL, Kim SZ. Pancreatic involvement in patients with inborn errors of metabolism. Orphanet J Rare Dis. 2021;16:37 [PMC free article: PMC7819202] [PubMed: 33472655]
• Imbard A, Garcia Segarra N, Tardieu M, Broué P, Bouchereau J, Pichard S, de Baulny HO, Slama A, Mussini C, Touati G, Danjoux M, Gaignard P, Vogel H, Labarthe F, Schiff M, Benoist JF. Long-term liver disease in methylmalonic and propionic acidemias. Mol Genet Metab. 2018;123:433-40. [PubMed: 29433791]
• Inoue S, Krieger I, Sarnaik A, Ravindranath Y, Fracassa M, Ottenbreit MJ. Inhibition of bone marrow stem cell growth in vitro by methylmalonic acid: a mechanism for pancytopenia in a patient with methylmalonic acidemia. Pediatr Res. 1981;15:95-8. [PubMed: 7254944]
• Irie R, Nakazawa A, Sakamoto S, Takeda M, Yanagi Y, Shimizu S, Uchida H, Fukuda A, Horikawa R, Kasahara M. Etiology of liver dysfunction after liver transplantation in children with metabolic disorders. Hepatol Res. 2020;50:635-42. [PubMed: 31957215]
• Jang JG, Oh SH, Kim YB, Kim SH, Yoo HW, Lee BH, Namgoong JM, Kim DY, Kim KH, Song GW, Moon DB, Hwang S, Lee SG, Kim KM. Efficacy of living donor liver transplantation in patients with methylmalonic acidemia. Pediatr Gastroenterol Hepatol Nutr. 2021;24:288-94. [PMC free article: PMC8128783] [PubMed: 34046332]
• Jiang YZ, Sun LY. The value of liver transplantation for methylmalonic acidemia. Front Pediatr. 2019;21;7:87.
• Jónsson H, Sulem P, Kehr B, Kristmundsdottir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadottir GA, Helgason EA, Helgason H, Gylfason A, Jonasdottir A, Jonasdottir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdottir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 2017;549:519-22. [PubMed: 28959963]
• Jusufi J, Suormala T, Burda P, Fowler B, Froese DS, Baumgartner MR. Characterization of functional domains of the cblD (MMADHC) gene product. J Inherit Metab Dis. 2014;37:841-9. [PubMed: 24722857]
• Kao CH, Liu MY, Liu TT, Hsiao KJ, Cheng KH, Huang CH, Lin HY, Niu DM: Growth hormone therapy in neonatal patients with methylmalonic acidemia. J Chin Med Assoc. 2009, 72:462-7. [PubMed: 19762313]
• Kaplan P, Ficicioglu C, Mazur AT, Palmieri MJ, Berry GT (2006) Liver transplantation is not curative for methylmalonic acidopathy caused by methylmalonyl-CoA mutase deficiency. Mol Genet Metab 88:322-6 [PubMed: 16750411]
• Kasahara M, Horikawa R, Tagawa M, Uemoto S, Yokoyama S, Shibata Y, Kawano T, Kuroda T, Honna T, Tanaka K, Saeki M. Current role of liver transplantation for methylmalonic acidemia: a review of the literature. Pediatr Transplant. 2006;10:943-7. [PubMed: 17096763]
• Kasahara M, Sakamoto S, Horikawa R, Koji U, Mizuta K, Shinkai M, Takahito Y, Taguchi T, Inomata Y, Uemoto S, Tatsuo K, Kato S. Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry. Pediatr Transplant. 2014;18:6-15. [PubMed: 24283623]
• Kayler LK, Merion RM, Lee S, Sung RS, Punch JD, Rudich SM, Turcotte JG, Campbell DA Jr, Holmes R, Magee JC (2002) Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 6:295-300 [PubMed: 12234269]
• KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis. 2009;53:S11-104. [PubMed: 19231749]
• Kiykim E, Oguz O, Duman C, Zubarioglu T, Cansever MS, Zeybek ACA. Long-term N-carbamylglutamate treatment of hyperammonemia in patients with classic organic acidemias. Mol Genet Metab Rep. 2021;26:100715. [PMC free article: PMC7851327] [PubMed: 33552909]
• Kölker S, Garcia-Cazorla A, Valayannopoulos V, Lund AM, Burlina AB, Sykut-Cegielska J, Wijburg FA, Teles EL, Zeman J, Dionisi-Vici C, Barić I, Karall D, Augoustides-Savvopoulou P, Aksglaede L, Arnoux JB, Avram P, Baumgartner MR, Blasco-Alonso J, Chabrol B, Chakrapani A, Chapman K, I Saladelafont EC, Couce ML, de Meirleir L, Dobbelaere D, Dvorakova V, Furlan F, Gleich F, Gradowska W, Grünewald S, Jalan A, Häberle J, Haege G, Lachmann R, Laemmle A, Langereis E, de Lonlay P, Martinelli D, Matsumoto S, Mühlhausen C, de Baulny HO, Ortez C, Peña-Quintana L, Ramadža DP, Rodrigues E, Scholl-Bürgi S, Sokal E, Staufner C, Summar ML, Thompson N, Vara R, Pinera IV, Walter JH, Williams M, Burgard P. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015a;38:1041-57. [PubMed: 25875215]
• Kölker S, Valayannopoulos V, Burlina AB, Sykut-Cegielska J, Wijburg FA, Teles EL, Zeman J, Dionisi-Vici C, Barić I, Karall D, Arnoux JB, Avram P, Baumgartner MR, Blasco-Alonso J, Boy SP, Rasmussen MB, Burgard P, Chabrol B, Chakrapani A, Chapman K, Cortès I Saladelafont E, Couce ML, de Meirleir L, Dobbelaere D, Furlan F, Gleich F, González MJ, Gradowska W, Grünewald S, Honzik T, Hörster F, Ioannou H, Jalan A, Häberle J, Haege G, Langereis E, de Lonlay P, Martinelli D, Matsumoto S, Mühlhausen C, Murphy E, de Baulny HO, Ortez C, Pedrón CC, Pintos-Morell G, Pena-Quintana L, Ramadža DP, Rodrigues E, Scholl-Bürgi S, Sokal E, Summar ML, Thompson N, Vara R, Pinera IV, Walter JH, Williams M, Lund AM, Garcia-Cazorla A. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis. 2015b;38:1059-74. [PubMed: 25875216]
• Korf B, Wallman JK, Levy HL (1986) Bilateral lucency of the globus pallidus complicating methylmalonic acidemia. Ann Neurol 20:364-6 [PubMed: 3767321]
• Kruszka PS, Manoli I, Sloan JL, Kopp JB, Venditti CP. Renal growth in isolated methylmalonic acidemia. Genet Med. 2013;15:990-6. [PMC free article: PMC4149057] [PubMed: 23639900]
• Ktena YP, Paul SM, Hauser NS, Sloan JL, Gropman A, Manoli I, Venditti CP. Delineating the spectrum of impairments, disabilities, and rehabilitation needs in methylmalonic acidemia (MMA). Am J Med Genet A. 2015a;167A:2075-84. [PMC free article: PMC9017244] [PubMed: 25959030]
• Ktena YP, Ramstad T, Baker EH, Sloan JL, Mannes AJ, Manoli I, Venditti CP. Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders: a review of theoretical concerns and clinical experiences in 28 patients. J Inherit Metab Dis. 2015b;38:847-53. [PMC free article: PMC5577977] [PubMed: 25985870]
• Ledley FD, Levy HL, Shih VE, Benjamin R, Mahoney MJ. Benign methylmalonic aciduria. N Engl J Med. 1984;311:1015-8. [PubMed: 6148691]
• Lempp TJ, Suormala T, Siegenthaler R, Baumgartner ER, Fowler B, Steinmann B, Baumgartner MR (2007) Mutation and biochemical analysis of 19 probands with mut0 and 13 with mut- methylmalonic aciduria: identification of seven novel mutations. Mol Genet Metab. 90:284-90. [PubMed: 17113806]
• Leonard JV, Vijayaraghavan S, Walter JH (2003) The impact of screening for propionic and methylmalonic acidaemia. Eur J Pediatr 162:S21-4 [PubMed: 14586648]
• Lerner-Ellis JP, Dobson CM, Wai T, Watkins D, Tirone JC, Leclerc D, Dore C, Lepage P, Gravel RA, Rosenblatt DS (2004) Mutations in the MMAA gene in patients with the cblA disorder of vitamin B12 metabolism. Hum Mutat 24:509-16 [PubMed: 15523652]
• Lerner-Ellis JP, Gradinger AB, Watkins D, Tirone JC, Villeneuve A, Dobson CM, Montpetit A, Lepage P, Gravel RA, Rosenblatt DS (2006) Mutation and biochemical analysis of patients belonging to the cblB complementation class of vitamin B12-dependent methylmalonic aciduria. Mol Genet Metab. 87:219-25. [PubMed: 16410054]
• Levtova A, Waters PJ, Buhas D, Lévesque S, Auray-Blais C, Clarke JTR, Laframboise R, Maranda B, Mitchell GA, Brunel-Guitton C, Braverman NE. Combined malonic and methylmalonic aciduria due to ACSF3 mutations: Benign clinical course in an unselected cohort. J Inherit Metab Dis. 2019;42:107-16. [PubMed: 30740739]
• Liang L, Shuai R, Yu Y, QIu W, Shen L, Qu S, Wei H, Chen Y, Yang C, Xu P, Chen X, Zou H, Feng J, Niu T, Hu H, Ye J, Zhang H, Lu D, Gong Z, Zhan X, Ji W, Yu Y, Gu X, Han L. A rare mutation c.1663G > A (p.A555T) in the MMUT gene associated with mild clinical and biochemical phenotypes of methylmalonic acidemia in 30 Chinese patients. Orphanet J Rare Dis. 2021;16:22. [PMC free article: PMC7792044] [PubMed: 33413471]
• Longo N, Price LB, Gappmaier E, Cantor NL, Ernst SL, Bailey C, Pasquali M. Anaplerotic therapy in propionic acidemia. Mol Genet Metab. 2017;122:51-9. [PMC free article: PMC5612888] [PubMed: 28712602]
• Longo N, Sass JO, Jurecka A, Vockley J. Biomarkers for drug development in propionic and methylmalonic acidemias. J Inherit Metab Dis. 2022;45:132-43. [PMC free article: PMC9303879] [PubMed: 35038174]
• Lubrano R, Perez B, Elli M. Methylmalonic acidemia and kidney transplantation. Pediatr Nephrol. 2013;28:2067-8. [PubMed: 23793882]
• Luciani A, Schumann A, Berquez M, Chen Z, Nieri D, Failli M, Debaix H, Festa BP, Tokonami N, Raimondi A, Cremonesi A, Carrella D, Forny P, Kölker S, Diomedi Camassei F, Diaz F, Moraes CT, Di Bernardo D, Baumgartner MR, Devuyst O. Impaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency. Nat Commun. 2020;11:970. [PMC free article: PMC7033137] [PubMed: 32080200]
• MacFarland S, Hartung H. Pancytopenia in a patient with methylmalonic acidemia. Blood. 2015;125:1840. [PubMed: 25927084]
• Malvagia S, Haynes, CA, Grisotto L, Ombrone D, Funghini S, Moretti E, McGreevy KS, Biggeri A, Guerrini R, Yahyaoui R, Garg U, Seeterlin M, Chace D, De Jesus VR, la Marca G. Heptadecanoylcarnitine (C17) a novel candidate biomarker for newborn screening of propionic and methylmalonic acidemias. Clin Chim Acta. 2015;450:342-8. [PMC free article: PMC5577792] [PubMed: 26368264]
• Manoli I, Myles JG, Sloan JL, Carrillo-Carrasco N, Morava E, Strauss KA, Morton H, Venditti CP. A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 2: cobalamin C deficiency. Genet Med. 2016a;18:396-404. [PMC free article: PMC4752912] [PubMed: 26270766]
• Manoli I, Myles JG, Sloan JL, Shchelochkov OA, Venditti CP. A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 1: isolated methylmalonic acidemias. Genet Med. 2016b;18:386-95. [PMC free article: PMC4752925] [PubMed: 26270765]
• Manoli I, Pass AR, Harrington EA, Sloan JL, Gagné J, McCoy S, Bell SL, Hattenbach JD, Leitner BP, Duckworth CJ, Fletcher LA, Cassimatis TM, Galaretta CI, Thurm A, Snow J, Van Ryzin C, Ferry S, Ah Mew N, Shchelochkov OA, Chen KY, Venditti CP. ¹³C- propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA). Genet Med. 2021;23:1522-33. [PMC free article: PMC8354855] [PubMed: 33820958]
• Manoli I, Sysol JR, Epping MW, Li L, Wang C, Sloan JL, Pass A, Gagné J, Ktena YP, Li L, Trivedi NS, Ouattara B, Zerfas PM, Hoffmann V, Abu-Asab M, Tsokos MG, Kleiner DE, Garone C, Cusmano-Ozog K, Enns GM, Vernon HJ, Andersson HC, Grunewald S, Elkahloun AG, Girard CL, Schnermann J, DiMauro S, Andres-Mateos E, Vandenberghe LH, Chandler RJ, Venditti CP. FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. JCI Insight. 2018;3:e124351 [PMC free article: PMC6328030] [PubMed: 30518688]
• Manoli I, Sysol JR, Li L, Houillier P, Garone C, Wang C, Zerfas PM, Cusmano-Ozog K, Young S, Trivedi NS, Cheng J, Sloan JL, Chandler RJ, Abu-Asab M, Tsokos M, Elkahloun AG, Rosen S, Enns GM, Berry GT, Hoffmann V, DiMauro S, Schnermann J, Venditti CP. Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. Proc Natl Acad Sci U S A. 2013;110:13552-7. [PMC free article: PMC3746875] [PubMed: 23898205]
• Marble M, Copeland S, Khanfar N, Rosenblatt DS. Neonatal vitamin B12 deficiency secondary to maternal subclinical pernicious anemia: identification by expanded newborn screening. J Pediatr. 2008;152:731-3. [PubMed: 18410783]
• Marcadier JL, Smith AM, Pohl D, Schwartzentruber J, Al-Dirbashi OY; FORGE Canada Consortium, Majewski J, Ferdinandusse S, Wanders RJ, Bulman DE, Boycott KM, Chakraborty P, Geraghty MT. Mutations in ALDH6A1 encoding methylmalonate semialdehyde dehydrogenase are associated with dysmyelination and transient methylmalonic aciduria. Orphanet J Rare Dis. 2013;8:98. [PMC free article: PMC3710243] [PubMed: 23835272]
• Marcellino A, Guido CA, Bloise S, Mallardo S, Isoldi S, Del Giudice E, Dilillo A, Martucci V, Sanseviero M, Iorfida D, Spalice A, Lubrano R. Physical and Neurological Development of a Girl Born to a Mother with Methylmalonic Acidemia and Kidney Transplantation and Review of the Literature. Children (Basel). 2021;8:1013. [PMC free article: PMC8619094] [PubMed: 34828726]
• Marelli C, Fouilhoux A, Benoist JF, De Lonlay P, Guffon-Fouilhoux N, Brassier A, Cano A, Chabrol B, Pennisi A, Schiff M, Acquaviva C, Murphy E, Servais A, Lachmann R. Very long-term outcomes in 23 patients with cblA type methylmalonic acidemia. J Inherit Metab Dis. 2022. Epub ahead of print. [PMC free article: PMC9540587] [PubMed: 35618652]
• Marquard J, el Scheich T, Klee D, Schmitt M, Meissner T, Mayatepek E, Oh J. Chronic pancreatitis in branched-chain organic acidurias—a case of methylmalonic aciduria and an overview of the literature. Eur J Pediatr. 2011;170:241-5 [PubMed: 20924605]
• Martens DH, Bakker JA, van der Meer SB, Spaapen LJ (2002) Unexplained familial benign methylmalonic aciduria. Eur J Pediatr 161:219-20 [PubMed: 12014390]
• Martínez MA, Rincón A, Desviat LR, Merinero B, Ugarte M, Pérez B. Genetic analysis of three genes causing isolated methylmalonic acidemia: identification of 21 novel allelic variants. Mol Genet Metab. 2005;84:317-25. [PubMed: 15781192]
• Martinez Alvarez L, Jameson E, Parry NR, Lloyd C, Ashworth JL. Optic neuropathy in methylmalonic acidemia and propionic acidemia. Br J Ophthalmol. 2016;100:98-104. [PubMed: 26209586]
• Matsui SM, Mahoney MJ, Rosenberg LE (1983) The natural history of the inherited methylmalonic acidemias. N Engl J Med 308:857-61 [PubMed: 6132336]
• McGuire MM, Jones BA, Hull MA, Misra MV, Smithers CJ, Feins NR, Jenkins RL, Lillehei CW, Harmon WE, Jonas MM, Kim HB. Combined en bloc liver-double kidney transplantation in an infant with IVC thrombosis. Pediatr Transplant. 2011;15:E142-4. [PubMed: 20412506]
• Mc Guire PJ, Parikh A, Diaz GA. Profiling of oxidative stress in patients with inborn errors of metabolism. Mol Genet Metab. 2009;98:173-80. [PMC free article: PMC2915835] [PubMed: 19604711]
• McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, Åhlman H, Allen JJ, Antonozzi I, Archer S, Au S, Auray-Blais C, Baker M, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med. 2011;13:230-54. [PubMed: 21325949]
• Molema F, Gleich F, Burgard P, van der Ploeg AT, Summar ML, Chapman KA, Barić I, Lund AM, Kölker S, Williams M, et al. Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea-cycle disorders: on the basis of information from a European multicenter registry. J Inherit Metab Dis. 2019;42:1162-75 [PubMed: 30734935]
• Molema F, Haijes HA, Janssen MC, Bosch AM, van Spronsen FJ, Mulder MF, Verhoeven-Duif NM, Jans JJM, van der Ploeg AT, Wagenmakers MA, Rubio-Gozalbo ME, Brouwers MCGJ, de Vries MC, Fuchs S, Langendonk JG, Rizopoulos D, van Hasselt PM, Williams M. High protein prescription in methylmalonic and propionic acidemia patients and its negative association with long-term outcome. Clin Nutr. 2021a;40:3622-30. [PubMed: 33451859]
• Molema F, Jacobs EH, Onkenhout W, Schoonderwoerd GC, Langendonk JG, Williams M. Fibroblast growth factor 21 as a biomarker for long-term complications in organic acidemias. J Inherit Metab Dis. 2018;41:1179-87. [PMC free article: PMC6327009] [PubMed: 30159853]
• Molema F, Martinelli D, Hörster F, Kölker S, Tangeraas T, de Koning B, Dionisi-Vici C, Williams M, et al. Liver and/or kidney transplantation in amino and organic acid-related inborn errors of metabolism: an overview on European data. J Inherit Metab Dis. 2021b;44:593-605. [PMC free article: PMC8247334] [PubMed: 32996606]
• Molema F, Williams M, Langendonk J, Darwish-Murad S, van de Wetering J, Jacobs E, Onkenhout W, Brusse E, van der Eerden A, Wagenmakers M. Neurotoxicity including posterior reversible encephalopathy syndrome after initiation of calcineurin inhibitors in transplanted methylmalonic acidemia patients: Two case reports and review of the literature. JIMD Rep. 2020;51:89-104. [PMC free article: PMC7012740] [PubMed: 32071844]
• Morath MA, Hörster F, Sauer SW. Renal dysfunction in methylmalonic acidurias: review for the pediatric nephrologist. Pediatr Nephrol. 2013;28:227-35. [PubMed: 22814947]
• Morava E, Steuerwald U, Carrozzo R, Kluijtmans LA, Joensen F, Santer R, Dionisi-Vici C, Wevers RA (2009) Dystonia and deafness due to SUCLA2 defect; Clinical course and biochemical markers in 16 children. Mitochondrion. 9:438-42. [PubMed: 19666145]
• Morel CF, Watkins D, Scott P, Rinaldo P, Rosenblatt DS (2005) Prenatal diagnosis for methylmalonic acidemia and inborn errors of vitamin B12 metabolism and transport. Mol Genet Metab. 86:160-71. [PubMed: 16150626]
• Morioka D, Kasahara M, Horikawa R, Yokoyama S, Fukuda A, Nakagawa A (2007) Efficacy of living donor liver transplantation for patients with methylmalonic acidemia. Am J Transplant 7:2782-7 [PubMed: 17908273]
• Nicolaides P, Leonard J, Surtees R (1998) Neurological outcome of methylmalonic acidaemia. Arch Dis Child 78:508-12 [PMC free article: PMC1717592] [PubMed: 9713004]
• Niemi AK, Kim IK, Krueger CE, Cowan TM, Baugh N, Farrell R, Bonham CA, Concepcion W, Esquivel CO, Enns GM. Treatment of methylmalonic acidemia by liver or combined liver-kidney transplantation. J Pediatr. 2015;166:1455-61.e1. [PubMed: 25771389]
• Nizon M, Ottolenghi C, Valayannopoulos V, Arnoux JB, Barbier V, Habarou F, Desguerre I, Boddaert N, Bonnefont JP, Acquaviva C, Benoist JF, Rabier D, Touati G, de Lonlay P. Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias. Orphanet J Rare Dis. 2013;8:148. [PMC free article: PMC4016503] [PubMed: 24059531]
• Noone D, Riedi M, Atkinson P, Avitzur Y, Sharma AP, Filler G, Siriwardena K, Prasad C. Kidney disease and organ transplantation in methylmalonic acidemia. Pediatr Transplant. 2019;23:e13407. [PubMed: 30973671]
• Nyhan WL, Fawcett N, Ando T, Rennert OM, Julius RL. Response to dietary therapy in B 12 unresponsive methylmalonic acidemia. Pediatrics. 1973;51:539-48. [PubMed: 4707869]
• Nyhan WL, Gargus JJ, Boyle K, Selby R, Koch R (2002) Progressive neurologic disability in methylmalonic acidemia despite transplantation of the liver. Eur J Pediatr 161:377-9 [PubMed: 12111189]
• O'Shea CJ, Sloan JL, Wiggs EA, Pao M, Gropman A, Baker EH, Manoli I, Venditti CP, Snow J. Neurocognitive phenotype of isolated methylmalonic acidemia. Pediatrics. 2012;129:e1541-51. [PMC free article: PMC3362903] [PubMed: 22614770]
• Ostergaard E, Hansen FJ, Sorensen N, Duno M, Vissing J, Larsen PL, Faeroe O, Thorgrimsson S, Wibrand F, Christensen E, Schwartz M (2007) Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. Brain 130:853-61 [PubMed: 17287286]
• Pajares S, Arranz JA, Ormazabal A, Del Toro M, García-Cazorla Á, Navarro-Sastre A, López RM, Meavilla SM, de Los Santos MM, García-Volpe C, de Aledo-Castillo JMG, Argudo A, Marín JL, Carnicer C, Artuch R, Tort F, Gort L, Fernández R, García-Villoria J, Ribes A. Implementation of second-tier tests in newborn screening for the detection of vitamin B₁₂ related acquired and genetic disorders: results on 258,637 newborns. Orphanet J Rare Dis. 2021;16:195. [PMC free article: PMC8086297] [PubMed: 33931066]
• Pangilinan F, Mitchell A, VanderMeer J, Molloy AM, Troendle J, Conley M, Kirke PN, Sutton M, Sequeira JM, Quadros EV, Scott JM, Mills JL, Brody LC. Transcobalamin II receptor polymorphisms are associated with increased risk for neural tube defects. J Med Genet. 2010;47:677-85. [PMC free article: PMC4112773] [PubMed: 20577008]
• Pangilinan F, Watkins D, Bernard D, Chen Y, Dong N, Wu Q, Ozel-Abaan H, Kaur M, Caggana M, Morrissey M, Browne ML, Mills JL, Van Ryzin C, Shchelochkov O, Sloan J, Venditti CP, Sarafoglou K, Rosenblatt DS, Kay DM, Brody LC. Probing the functional consequence and clinical relevance of CD320 p.E88del, a variant in the transcobalamin receptor gene. Am J Med Genet A. 2022;188:1124-41. [PMC free article: PMC8923979] [PubMed: 35107211]
• Pappas KB, Younan M, Conway R. Transcobalamin receptor deficiency in seven asymptomatic patients ascertained through newborn screening. Am J Med Genet A. 2022;188:1102-8. [PubMed: 34978764]
• Park KC, Krywawych S, Richard E, Desviat LR, Swietach P. Cardiac complications of propionic and other inherited organic acidemias. Front Cardiovasc Med. 2020;7:617451. [PMC free article: PMC7782273] [PubMed: 33415129]
• Pillai NR, Stroup BM, Poliner A, Rossetti L, Rawls B, Shayota BJ, Soler-Alfonso C, Tunuguntala HP, Goss J, Craigen W, Scaglia F, Sutton VR, Himes RW, Burrage LC. Liver transplantation in propionic and methylmalonic acidemia: A single center study with literature review. Mol Genet Metab. 2019;128:431-43. [PMC free article: PMC6898966] [PubMed: 31757659]
• Pinar-Sueiro S, Martínez-Fernández R, Lage-Medina S, Aldamiz-Echevarria L, Vecino E. Optic neuropathy in methylmalonic acidemia: the role of neuroprotection. J Inherit Metab Dis. 2010;33 Suppl 3:S199-203. [PubMed: 20449661]
• Pinto A, Evans S, Daly A, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei SM, Bollhalder S, Cassiman D, Champion H, Chan H, Corthouts K, Dalmau J, Boer F, Laet C, Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Hansen KK, Horst NT, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs GE, Kok I, Kowalik A, Laguerre C, Verge SL, Liguori A, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Och U, Robert M, Rocha JC, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Skeath R, Stolen LH, Terry A, Timmer C, Tomlinson L, Tooke A, Kerckhove KV, van Dam E, Hurk DVD, Ploeg LV, van Driessche M, van Rijn M, Wegberg AV, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White F, White L, Zweers H, MacDonald A. Dietary practices in methylmalonic acidaemia: a European survey. J Pediatr Endocrinol Metab. 2020;33:147-55. [PubMed: 31846426]
• Plessl T, Bürer C, Lutz S, Yue WW, Baumgartner MR, Froese DS. Protein destabilization and loss of protein-protein interaction are fundamental mechanisms in cblA-type methylmalonic aciduria. Hum Mutat. 2017;38:988-1001. [PubMed: 28497574]
• Potter SL, Venkatramani R, Wenderfer S, Graham BH, Vasudevan SA, Sher A, Wu H, Wheeler DA, Yang Y, Eng CM, Gibbs RA, Roy A, Plon SE, Parsons DW. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. Pediatr Blood Cancer. 2017;64:.10.1002/pbc.26286 [PMC free article: PMC5469213] [PubMed: 27748010] [CrossRef]
• Prada CE, Al Jasmi F, Kirk EP, Hopp M, Jones O, Leslie ND, Burrow TA. Cardiac disease in methylmalonic acidemia. J Pediatr. 2011;159:862-4. [PubMed: 21784454]
• Pupavac M, Tian X, Chu J, Wang G, Feng Y, Chen S, Fenter R, Zhang VW, Wang J, Watkins D, Wong LJ, Rosenblatt DS. Added value of next generation gene panel analysis for patients with elevated methylmalonic acid and no clinical diagnosis following functional studies of vitamin B12 metabolism. Mol Genet Metab. 2016;117:363-8. [PubMed: 26827111]
• Quadros EV, Lai SC, Nakayama Y, Sequeira JM, Hannibal L, Wang S, Jacobsen DW, Fedosov S, Wright E, Gallagher RC, Anastasio N, Watkins D, Rosenblatt DS. Positive newborn screen for methylmalonic aciduria identifies the first mutation in TCblR/CD320, the gene for cellular uptake of transcobalamin-bound vitamin B(12). Hum Mutat. 2010;31:924-9. [PMC free article: PMC2909035] [PubMed: 20524213]
• Radmanesh A, Zaman T, Ghanaati H, Molaei S, Robertson RL, Zamani AA. Methylmalonic acidemia: brain imaging findings in 52 children and a review of the literature. Pediatr Radiol. 2008;38:1054-61. [PubMed: 18636250]
• Raval DB, Merideth M, Sloan JL, Braverman NE, Conway RL, Manoli I, Venditti CP. Methylmalonic acidemia (MMA) in pregnancy: a case series and literature review. J Inherit Metab Dis. 2015;38:839-46. [PMC free article: PMC4496322] [PubMed: 25567501]
• Ruzkova K, Weingarten TN, Larson KJ, Friedhoff RJ, Gavrilov DK, Sprung J. Anesthesia and organic aciduria: is the use of lactated Ringer's solution absolutely contraindicated? Paediatr Anaesth. 2015;25:807-17. [PubMed: 25943188]
• Sakamoto R, Nakamura K, Kido J, Matsumoto S, Mitsubuchi H, Inomata Y, Endo F. Improvement in the prognosis and development of patients with methylmalonic acidemia after living donor liver transplant. Pediatr Transplant. 2016;20:1081-6. [PubMed: 27670840]
• Sass JO, Walter M, Shield JP, Atherton AM, Garg U, Scott D, Woods CG, Smith LD. 3-Hydroxyisobutyrate aciduria and mutations in the ALDH6A1 gene coding for methylmalonate semialdehyde dehydrogenase. J Inherit Metab Dis. 2012;35:437-42. [PubMed: 21863277]
• Schiff M, Ogier de Baulny H, Bard G, Barlogis V, Hamel C, Moat SJ, Odent S, Shortland G, Touati G, Giraudier S. Should transcobalamin deficiency be treated aggressively? J Inherit Metab Dis. 2010;33:223-9. [PubMed: 20352340]
• Scolamiero E, Villani GR, Ingenito L, Pecce R, Albano L, Caterino M, di Girolamo MG, Di Stefano C, Franzese I, Gallo G, Ruoppolo M. Maternal vitamin B12 deficiency detected in expanded newborn screening. Clin Biochem. 2014;47:312-7. [PubMed: 25204964]
• Sénac JS, Chandler RJ, Sysol JR, Li L, Venditti CP. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery. Gene Ther. 2012;19:385-91. [PMC free article: PMC3382069] [PubMed: 21776024]
• Sewell AC, Poets CF, Degen I, Stöss H, Pontz BF. The spectrum of free neuraminic acid storage disease in childhood: clinical, morphological and biochemical observations in three non-Finnish patients. Am J Med Genet. 1996;63:203-8. [PubMed: 8723111]
• Shigematsu Y, Hirano S, Hata I, Tanaka Y, Sudo M, Sakura N, Tajima T, Yamaguchi S (2002) Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan. J Chromatogr B Analyt Technol Biomed Life Sci 776:39-48 [PubMed: 12127323]
• Sloan JL, Johnston JJ, Manoli I, Chandler RJ, Krause C, Carrillo-Carrasco N, Chandrasekaran SD, Sysol JR, O'Brien K, Hauser NS, Sapp JC, Dorward HM, Huizing M; NIH Intramural Sequencing Center Group, Barshop BA, Berry SA, James PM, Champaigne NL, de Lonlay P, Valayannopoulos V, Geschwind MD, Gavrilov DK, Nyhan WL, Biesecker LG, Venditti CP. Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria. Nat Genet. 2011;43:883-6. [PMC free article: PMC3163731] [PubMed: 21841779]
• Sloan JL, Manoli I, Venditti CP. Liver or combined liver-kidney transplantation for patients with isolated methylmalonic acidemia: who and when? J Pediatr. 2015;166:1346-50. [PubMed: 25882873]
• Sniderman LC, Lambert M, Giguere R, Auray-Blais C, Lemieux B, Laframboise R, Rosenblatt DS, Treacy EP (1999) Outcome of individuals with low-moderate methylmalonic aciduria detected through a neonatal screening program. J Pediatr 134:675-80 [PubMed: 10356133]
• Spada M, Calvo PL, Brunati A, Peruzzi L, Dell'Olio D, Romagnoli R, Porta F. Liver transplantation in severe methylmalonic acidemia: The sooner, the better. J Pediatr. 2015;167:1173. [PubMed: 26362094]
• Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368:149-60. [PubMed: 23301732]
• Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139:1197-207. [PMC free article: PMC7497289] [PubMed: 32596782]
• Strømme P, Stokke O, Jellum E, Skjeldal OH, Baumgartner R (1995) Atypical methylmalonic aciduria with progressive encephalopathy, microcephaly and cataract in two siblings--a new recessive syndrome? Clin Genet 48:1-5 [PubMed: 7586637]
• Stucki M, Coelho D, Suormala T, Burda P, Fowler B, Baumgartner MR. Molecular mechanisms leading to three different phenotypes in the cblD defect of intracellular cobalamin metabolism. Hum Mol Genet. 2012;21:1410-8. [PubMed: 22156578]
• Subramanian C, Frank MW, Tangallapally R, Yun MK, Edwards A, White SW, Lee RE, Rock CO, Jackowski S. Pantothenate kinase activation relieves coenzyme A sequestration and improves mitochondrial function in mice with propionic acidemia. Sci Transl Med. 2021;13:eabf5965. [PMC free article: PMC8830021] [PubMed: 34524863]
• Sumathipala D, Strømme P, Fattahi Z, Lüders T, Sheng Y, Kahrizi K, Einarsen IH, Sloan JL, Najmabadi H, van den Heuvel L, Wevers RA, Guerrero-Castillo S, Mørkrid L, Valayannopoulos V, Backe PH, Venditti CP, van Karnebeek CD, Nilsen H, Frengen E, Misceo D. ZBTB11 dysfunction: spectrum of brain abnormalities, biochemical signature and cellular consequences. Brain. 2022;145:2602-16. [PMC free article: PMC9337812] [PubMed: 35104841]
• Therrell BL Jr, Lloyd-Puryear MA, Camp KM, Mann MY. Inborn errors of metabolism identified via newborn screening: Ten-year incidence data and costs of nutritional interventions for research agenda planning. Mol Genet Metab. 2014;113:14-26. [PMC free article: PMC4177968] [PubMed: 25085281]
• Traber G, Baumgartner MR, Schwarz U, Pangalu A, Donath MY, Landau K. Subacute bilateral visual loss in methylmalonic acidemia. J Neuroophthalmol. 2011;31:344-6. [PubMed: 21873889]
• Trakadis YJ, Alfares A, Bodamer OA, Buyukavci M, Christodoulou J, Connor P, Glamuzina E, Gonzalez-Fernandez F, Bibi H, Echenne B, Manoli I, Mitchell J, Nordwall M, Prasad C, Scaglia F, Schiff M, Schrewe B, Touati G, Tchan MC, Varet B, Venditti CP, Zafeiriou D, Rupar CA, Rosenblatt DS, Watkins D, Braverman N. Update on transcobalamin deficiency: clinical presentation, treatment and outcome. J Inherit Metab Dis. 2014;37:461-73. [PubMed: 24305960]
• Treacy E, Arbour L, Chessex P, Graham G, Kasprzak L, Casey K, Bell L, Mamer O, Scriver CR (1996) Glutathione deficiency as a complication of methylmalonic acidemia: response to high doses of ascorbate. J Pediatr 129:445-8 [PubMed: 8804337]
• Tuchman M, Caldovic L, Daikhin Y, Horyn O, Nissim I, Nissim I, Korson M, Burton B, Yudkoff M. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64:213-7. [PMC free article: PMC2640836] [PubMed: 18414145]
• Tuncel AT, Boy N, Morath MA, Hörster F, Mütze U, Kölker S. Organic acidurias in adults:late complications and management. J Inherit Metab Dis. 2018;41:765-76. [PubMed: 29335813]
• Turgeon CT, Magera MJ, Cuthbert CD, Loken PR, Gavrilov DK, Tortorelli S, Raymond KM, Oglesbee D, Rinaldo P, Matern D. Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. Clin Chem 2010;56:1686-95 [PubMed: 20807894]
• Valayannopoulos V, Baruteau J, Delgado MB, Cano A, Couce ML, Del Toro M, Donati MA, Garcia-Cazorla A, Gil-Ortega D, Gomez-de Quero P, Guffon N, Hofstede FC, Kalkan-Ucar S, Coker M, Lama-More R, Martinez-Pardo Casanova M, Molina A, Pichard S, Papadia F, Rosello P, Plisson C, Le Mouhaer J, Chakrapani A. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. Orphanet J Rare Dis. 2016;11:32. [PMC free article: PMC4815113] [PubMed: 27030250]
• Valayannopoulos V, Hubert L, Benoist JF, Romano S, Arnoux JB, Chrétien D, Kaplan J, Fakhouri F, Rabier D, Rötig A, Lebre AS, Munnich A, de Keyzer Y, de Lonlay P. Multiple OXPHOS deficiency in the liver of a patient with CblA methylmalonic aciduria sensitive to vitamin B(12). J Inherit Metab Dis. 2009;32:159-62. [PubMed: 19277894]
• Van Calcar SC, Harding CO, Lyne P, Hogan K, Banerjee R, Sollinger H, Rieselbach RE, Wolff JA (1998) Renal transplantation in a patient with methylmalonic acidaemia. J Inherit Metab Dis 21:729-37 [PubMed: 9819702]
• van der Meer SB, Poggi F, Spada M, Bonnefont JP, Ogier H, Hubert P, Depondt E, Rapoport D, Rabier D, Charpentier C, et al. Clinical outcome of long-term management of patients with vitamin B12-unresponsive methylmalonic acidemia. J Pediatr. 1994;125:903-8. [PubMed: 7996362]
• van der Meer SB, Spaapen LJ, Fowler B, Jakobs C, Kleijer WJ, Wendel U. Prenatal treatment of a patient with vitamin B12-responsive methylmalonic acidemia. J Pediatr. 1990;117:923-6. [PubMed: 2246694]
• van't Hoff W, McKiernan PJ, Surtees RA, Leonard JV. Liver transplantation for methylmalonic acidaemia. Eur J Pediatr. 1999;158 Suppl 2:S70-4. [PubMed: 10603103]
• van 't Hoff WG, Dixon M, Taylor J, Mistry P, Rolles K, Rees L, Leonard JV. Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr. 1998;132:1043-4. [PubMed: 9627602]
• Vernon HJ, Sperati CJ, King JD, Poretti A, Miller NR, Sloan JL, Cameron AM, Myers D, Venditti CP, Valle D. A detailed analysis of methylmalonic acid kinetics during hemodialysis and after combined liver/kidney transplantation in a patient with mut (0) methylmalonic acidemia. J Inherit Metab Dis. 2014;37:899-907. [PMC free article: PMC4373418] [PubMed: 24961826]
• Wang C, Zhang YQ, Zhang SH, Meng YT, Lin SX, Cai CQ, Shu JB. A novel two-nucleotide deletion of MMADHC gene causing cblD disease in a Chinese family. Chin Med J (Engl). 2018;131:2477-9. [PMC free article: PMC6202588] [PubMed: 30334532]
• Wasserstein MP, Gaddipati S, Snyderman SE, Eddleman K, Desnick RJ, Sansaricq C (1999) Successful pregnancy in severe methylmalonic acidaemia. J Inherit Metab Dis 22:788-94 [PubMed: 10518278]
• Waters PJ, Thuriot F, Clarke JT, Gravel S, Watkins D, Rosenblatt DS, Lévesque S. Methylmalonyl-coA epimerase deficiency: a new case, with an acute metabolic presentation and an intronic splicing mutation in the MCEE gene. Mol Genet Metab Rep. 2016;9:19-24. [PMC free article: PMC5037260] [PubMed: 27699154]
• Weiss KJ, Röschinger W, Blessing H, Lotz-Havla AS, Schiergens KA, Maier EM. Diagnostic Challenges Using a 2-Tier Strategy for Methylmalonic Acidurias: Data from 1.2 Million Dried Blood Spots. Ann Nutr Metab. 2020;76:268-76. [PubMed: 32683363]
• Williams ZR, Hurley PE, Altiparmak UE, Feldon SE, Arnold GL, Eggenberger E, Mejico LJ (2009) Late onset optic neuropathy in methylmalonic and propionic acidemia. Am J Ophthalmol 147:929-33 [PubMed: 19243738]
• Worgan LC, Niles K, Tirone JC, Hofmann A, Verner A, Sammak A, Kucic T, Lepage P, Rosenblatt DS (2006) Spectrum of mutations in mut methylmalonic acidemia and identification of a common Hispanic mutation and haplotype. Hum Mutat 27:31-43 [PubMed: 16281286]
• Yano S, Li L, Le TP, Moseley K, Guedalia A, Lee J, Gonzalez I, Boles RG (2003) Infantile mitochondrial DNA depletion syndrome associated with methylmalonic aciduria and 3-methylcrotonyl-CoA and propionyl-CoA carboxylase deficiencies in two unrelated patients: a new phenotype of mtDNA depletion syndrome. J Inherit Metab Dis 26:481-8 [PubMed: 14518828]
• Yap S, Vara R, Morais A. Post-transplantation Outcomes in Patients with PA or MMA: A Review of the Literature. Adv Ther. 2020;37:1866-96. [PMC free article: PMC7141097] [PubMed: 32270363]
• Yu Y, Shuai R, Liang L, Qui W, Shen L, Wu S, Wei H, Chen Y, Yan C, Xu P, Chen XZou H, Feng J, Niu T, Hu H, Ye J, Zhang H, Lu D, Gong Z, Zhan X, Ji W, Gu Z, Han L. Different mutations in the MMUT gene are associated with the effect of vitamin B12 in a cohort of 266 Chinese patients with mut‐type methylmalonic acidemia: A retrospective study. Mol Genet Genomic Med. 2021;9: e1822. [PMC free article: PMC8606212] [PubMed: 34668645]
• Zsengellér ZK, Aljinovic N, Teot LA, Korson M, Rodig N, Sloan JL, Venditti CP, Berry GT, Rosen S. Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol. 2014;29:2139-46. [PubMed: 24865477]
• Zwickler T, Haege G, Riderer A, Hörster F, Hoffmann GF, Burgard P, Kölker S. Metabolic decompensation in methylmalonic aciduria: which biochemical parameters are discriminative? J Inherit Metab Dis. 2012;35:797-806. [PubMed: 22249333]